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Aim of the present investigation 1 
 
Diabetes mellitus (DM) is the commonest endocrine disorder that affects more than 
366 million persons with diabetes in the world today which is expected to rise to 552 
million by 2030. In India alone 61.3 million have diabetes by 2011 which is expected 
to rise to 101.2 million by 2030 (International Diabetes Federation). Diabetes mellitus 
consists of a group of syndromes characterized by hyperglycemia; altered metabolism 
of lipids, carbohydrates, and proteins; and an increased risk of complications from 
vascular disease (Rang et al., 2007). Most patients can be classified clinically as 
having either type 1 or type 2 diabetes mellitus. An attempt to control diabetes 
through changes in diet and level of physical activity is usually first-line management 
before beginning pharmacologic treatment. Many oral hypoglycemic agents such as 
biguanides and sulfonylureas are available for the treatment of diabetes mellitus for 
patients not responding adequately to diet alone or patients who require diet plus 
insulin (RoIkamp et al., 1996). 
Sulfonylurea class of drugs have established potential benefits such as lower dose, 
rapid onset, lower insulin levels and less-pronounced glucagonotropic effects, insulin-
sensitizing and insulin-mimetic affects. They lower blood glucose in patients with 
Type 2 diabetes by directly stimulating the acute release of insulin from functioning 
beta cells of pancreatic islet tissue by an unknown process that involves a 
sulfonylurea receptor on the beta cell and binding to the SUR1 subunits and block the 
ATP-sensitive K+ channel. The sulfonylureas have similar spectra of activities; thus 
their pharmacokinetic properties are their most distinctive characteristics. Although 
the rates of absorption of the different sulfonylureas vary, all are effectively absorbed 
from the gastrointestinal tract. However, food and hyperglycemia can reduce the 
absorption of sulfonylureas (Hardman and Limbird, 2001). 
However they are poorly soluble drugs with relatively high permeability through 
CaCo-2 cell monolayer's, which warrant it to be classified under BCS Class II 
classification (Frick et al., 1998; Lindenberg et al., 2004; Ning et al., 2011; Singh et 
al., 2012). It is effectively absorbed from the gastrointestinal tract, however, presence 
of food, certain dietary supplements and hyperglycemia can interfere with its 
dissolution and in turn its absorption (Ramon et al., 2000), and hence in view of the 
time required to reach an optimal concentration in plasma, sulfonylurea class of drugs 
may be more effective if given 30 minutes before meal (Hardman and Limbird, 2001). 
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Conversely, this might reduce patient compliance since if after taking the drug the 
patient is not able to have the meal it would result in severe hypoglycemia and if 
taken with meal, food sequentially would interfere with its absorption. Hence for 
efficient absorption of drugs from the gastrointestinal tract for improving their 
therapeutic efficacy, there is an imminent need for studies in designing novel 
strategies for their dissolution enhancement. 
The basic challenge faced by the researcher for the formulation of such poorly soluble 
drugs is the low oral bioavailability and erratic absorption of the drugs from the 
gastrointestinal tract due to their low saturation solubility and dissolution velocity. 
The low saturation solubility results in a low concentration gradient between the gut 
and blood vessel and leads to a limited transport of drug.(Gao et al., 2008) 
Various techniques like liposomes (Kumar et al., 2001), microemulsions (Bachhav 
and Patravale, 2009), solid-dispersions (Cirri et al., 2007; Ning et al., 2011; Valleri et 
al., 2004)  and inclusion complexes using cyclodextrins (Ammar et al., 2006; Klein et 
al., 2009; Singh et al., 2012) have been utilized for improving the dissolution 
characteristics of drugs from sulfonylurea class,but the application of novel drug 
delivery strategy for improving their dissolution characteristics is still lacking. 
Hence there is a need for development of a drug delivery strategy applicable to 
sulfonylurea class of drugs such as glibenclamide and glimepiride for improving 
dissolution characteristics. Novel drug delivery strategies such as nanosuspensions, 
self nanoemulsifying drug delivery systems, etc, could be studied for dissolution 
enhancement of such drugs. 
In light of this, the present investigation was carried out with the following objective. 
1. To select various antidiabetic drugs from sulfonylurea class suitable for 
dissolution enhancement. 
2. Design, development and optimize novel drug delivery strategies for their 
dissolution enhancement. 
3. Characterize and evaluate the prepared dosage forms. 
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2.1 Introduction to diabetes mellitus 
DM is a chronic metabolic disorder characterized by a high blood glucose 
concentration-hyperglycemia (fasting plasma glucose > 7.0 mmol/l, or plasma glucose 
> 11.1 mmol/l 2 hours after a meal)-caused by insulin deficiency, often combined 
with insulin resistance (Rang, Dale, Ritter, & Flower, 2007). Hyperglycaemia occurs 
because of uncontrolled hepatic glucose output and reduced uptake of glucose by 
skeletal muscle with reduced glycogen synthesis. When the renal threshold for 
glucose reabsorption is exceeded, glucose spills over into the urine (glycosuria) and 
causes an osmotic diuresis (polyuria), which, in turn, results in dehydration, thirst and 
increased drinking (polydipsia). Hyperglycaemia and diabetes are important causes of 
mortality and morbidity worldwide, through both direct clinical consequences and 
increased mortality from cardiovascular and kidney diseases (Nathan et al., 2009). 
2.2 There are two main types of DM 
Type 1 diabetes (previously known as insulin-dependent diabetes mellitus-IDDM-or 
juvenile-onset diabetes) 
Type 2 diabetes (previously known as non-insulin-dependent diabetes mellitus-
NIDDM-or maturity-onset diabetes). 
In type 1 diabetes, there is an absolute deficiency of insulin resulting from 
autoimmune destruction of  β cells. Without insulin treatment, such patients will 
ultimately die with diabetic ketoacidosis. 
Type 1 diabetic patients are usually young (children or adolescents) and not obese 
when they first develop symptoms. There is an inherited predisposition, with a 10-fold 
increased incidence in first-degree relatives of an index case, and strong associations 
with particular histocompatibility antigens (HLA types). The patient becomes overtly 
diabetic only when more than 90% of the β cells have been destroyed. This natural 
history provides a tantalizing prospect of intervening in the prediabetic stage, and a 
variety of strategies have been mooted, including immunosuppression, early insulin 
therapy, antioxidants, nicotinamide and many others, but so far these have 
disappointed (Hardman & Limbird, 2001). 
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Type 2 diabetes is accompanied both by insulin resistance (which precedes overt 
disease) and by impaired insulin secretion, each of which are important in its 
pathogenesis. Such patients are often obese and usually present in adult life, the 
incidence rising progressively with age as β -cell function declines. Treatment is 
initially dietary, although oral hypoglycaemic drugs usually become necessary, and 
about one-third of patients ultimately require insulin (Derosa & Sibilla, 2007). 
2.3 Treatment 
Diet is the main treatment combined with increased exercise. However patients 
insulin is mainly used for controlling diabetes mellitus. Patients not responding to 
insulin as well as dietary control are administered oral hypoglycemic agents, they are 
used to control symptoms from hyperglycaemia, as well as to limit microvascular 
complications (Sheehan, 2003). 
The main oral hypoglycaemic agents are metformin (a biguanide), sulfonylureas and 
other drugs that act on the sulfonylurea receptor, and glitazones.  
2.4 Introduction to sulfonylurea  
The sulfonylureas are divided into two groups or generations of agents. The first 
group of sulfonylureas includes tolbutamide, acetohexamide, tolazamide, and 
chlorpropamide. A second, more potent generation of hypoglycemic sulfonylureas has 
emerged, including glyburide (glibenclamide), glipizide, gliclazide, and glimepiride 
(Rang et al., 2007). 
2.4.1 Mechanism of Action 
Sulfonylureas cause hypoglycemia by stimulating insulin release from pancreatic β 
cells. Their effects in the treatment of diabetes, however, are more complex. The 
acute administration of sulfonylureas to type 2 DM patients increases insulin release 
from the pancreas. Sulfonylureas also may further increase insulin levels by reducing 
hepatic clearance of the hormone. In the initial months of sulfonylurea treatment, 
fasting plasma insulin levels and insulin responses to oral glucose challenges are 
increased. With chronic administration, circulating insulin levels decline to those that 
existed before treatment, but despite this reduction in insulin levels, reduced plasma 
glucose levels are maintained. The explanation for this is not clear, but it may relate to 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 4
Introduction 2 
 
reduced plasma glucose allowing circulating insulin to have more pronounced effects 
on its target tissues and to the fact that chronic hyperglycemia per se impairs insulin 
secretion (Groop, 1992). 
Sulfonylureas bind to the SUR1 subunits and block the ATP-sensitive K
+ 
channel The 
drugs thus resemble physiological secretagogues), which also lower the conductance 
of this channel. Reduced K
+
 conductance causes membrane depolarization and influx 
of Ca
2+ 
through voltage-sensitive Ca
2+ 
channels.  
2.4.2 Absorption, fate, and excretion.  
The sulfonylureas have similar spectra of activities; thus their pharmacokinetic 
properties are their most distinctive characteristics. Hyperglycemia per se inhibits 
gastric and intestinal motility and thus can retard the absorption of many drugs. In 
view of the time required to reach an optimal concentration in plasma, sulfonylureas 
with short half-lives such as glibenclamide and glimepiride may be more effective 
when given 30 minutes before eating (Hardman & Limbird, 2001). Sulfonylureas in 
plasma are largely (90% to 99%) bound to protein, especially albumin; plasma protein 
binding is least for chlorpropamide and greatest for glyburide (Groop, 1992). 
 The second-generation agents are approximately 100 times more potent than are 
those in the first group. Although their half-lives are short (3 to 5 hours), their 
hypoglycemic effects are evident for 12 to 24 hours, and they often can be 
administered once daily. The reason for the discrepancies between their half-lives and 
duration of action is not clear.  
2.4.3 Therapeutic uses.  
Sulfonylureas are used to control hyperglycemia in type 2 DM patients who cannot 
achieve appropriate control with changes in diet alone. In all patients, continued 
dietary restrictions are essential to maximize the efficacy of the sulfonylureas. 
Contraindications to the use of these drugs include type 1 DM, pregnancy, lactation, 
and for the older preparations, significant hepatic or renal insufficiency.  
Between 50% and 80% of properly selected patients will respond initially to an oral 
hypoglycemic agent. All the drugs appear to be equally efficacious. Concentrations of 
glucose often are lowered sufficiently to relieve symptoms of hyperglycemia but may 
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not reach normal levels. To the extent that complications of diabetes are related to 
hyperglycemia, the goal of treatment should be normalization of both fasting and 
postprandial glucose concentrations. About 5% to 10% of patients per year who 
respond initially to a sulfonylurea become secondary failures, as defined by 
unacceptable levels of hyperglycemia. This may occur as a result of a change in drug 
metabolism, progression of b-cell failure, change in dietary compliance, or 
misdiagnosis of a patient with slow-onset type 1 DM. Additional oral agent(s) can 
produce a satisfactory response, but most of these patients eventually will require 
insulin.  
2.4.5 Dose and regimen 
The initial daily dose of glyburide is 2.5 to 5 mg, and daily doses of more than 20 mg 
are not recommended. Therapy with glipizide usually is initiated with 5 mg given 
once daily. The maximal recommended daily dose is 40 mg; daily doses of more than 
15 mg should be divided. The starting dose of gliclazide is 40 to 80 mg/day, and the 
maximal daily dose is 320 mg. Glimepiride therapy can begin with doses as low as 
0.5 mg once per day. The maximal effective daily dose of the agent is 8 mg. 
Treatment with the sulfonylureas must be guided by the patient's response, which 
must be monitored frequently (Miyahara, 1992) 
Combinations of insulin and sulfonylureas have been used in some patients with type 
1 and type 2 DM. Studies in type 1 DM patients have provided no evidence that 
glucose control is improved by combination therapy. The results in type 2 DM 
patients have shown significant improvements in metabolic control. A prerequisite for 
a beneficial effect of combination therapy is residual b-cell activity; a short duration 
of diabetes also may predict a good response (Derosa & Sibilla, 2007). 
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2.5  Marketed formulations of some drugs from sulfonylurea class 
Brand name Drug Dose (mg) 
Glimicon Glimipiride 1,2,3,4  mg 
Amaryl Glimipiride 1, 2, 4 mg 
DiaBeta Glyburide (micronized) 1.25, 2.5, 5 mg 
Glynase Glyburide (micronized) 1.5, 3, 6 mg 
 
 2.6 Conclusion 
During the literature survey on treatment of Type II DM, it was seen that sulfonylurea 
class of drugs have now been the first line of treatment alone or in combination with 
other anti diabetic drugs. From the sulfonylurea class two drugs namely glimepiride 
and glibenclamide are apt candidates for improving the dissolution characteristics, 
since they are having very low half life (2-3 hrs) and a low dose (2-4 mg). Hence, this 
two drugs were selected for incorporation in to different drug delivery strategies for 
improving dissolution characteristics. 
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1. Introduction 
Self-emulsifying drug delivery systems (SEDDS) are relatively newer, lipid-based 
technological innovations with immense promise in enhancing the oral bioavailability 
of drugs. These formulations have been shown to reduce the slow and incomplete 
dissolution of a drug, facilitate the formation of its solubilized phase, increase the 
extent of its transportation via the intestinal lymphatic system, and bypass the P-
glycoprotein efflux, thereby augmenting drug absorption from the gastrointestinal 
(GI) tract. Self-emulsifying formulations are isotropic mixtures of drug, lipids (natural 
or synthetic oils), and emulsifiers (solid or liquid), usually with one or more 
hydrophilic co-solvents/co-emulsifiers (B. Singh, Bandopadhyay, Kapil, Singh, & 
Katare, 2009). 
SEDDS is a broad term encompassing emulsions with a droplet size ranging from a 
few nanometers to several microns. Depending upon the size of globules, these 
emulsions are characterized as concentrated microemulsions, nanoemulsions, or pre-
concentrates. Self microemulsified drug delivery system (SMEDDS) are formulations 
forming transparent microemulsions with an oil droplet size ranging between 100 and 
250 nm. Self-nanoemulsified drug delivery system (SNEDDS) is relatively a recent 
term indicating formulations with a globule size less than 100 nm (Nicolas. Anton & 
Vandamme, 2010). 
The SNEDDS formulation forms a clear dispersion instantaneously in the GI tract that 
remains stable on dilution. A typical SNEDDS formulation basically constitutes apt 
lipidic and emulsifying excipients having an inherent ability to solubilize the drug.  
As the release of a drug compound from SNEDDS takes place in the GI tract, the 
hydrophobic agent should remain solubilized for at least the time period relevant 
during GI absorption. Therefore, a typical SNEDDS formulation also contains a co-
emulsifier in addition to the essential lipid and emulsifier (Sarker, 2005). 
The following figure 2.1 illustrates the usual methodology pathways to prepare 
SNEDDS formulations and the eventual formation of the nanoemulsions following 
their dilution. These SNEDDS have to be ultimately formulated as an oral solution in 
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soft gelatin capsules or as solid dosage forms in hard gelatin capsules, depending on 
the final physical nature of the system as liquid or semisolid/solid, respectively 
 
Figure 2. 1 Schematic procedure for preparing SNEDDS (adapted from (B. Singh et al., 2009)) 
Depending upon the relative proportions of lipidic triglycerides, water-soluble or 
water-insoluble surfactant emulsifiers, and hydro- phobic co-emulsifiers or co-
solvents, the SNEDDS have been classified as Type I, II, III, III, and IV (P. Li et al., 
2009). 
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Table 2. 1 Classification of self nanoemulsifying drug delivery system 
Formulation Type I Type II Type III Type IV 
Excipients 
Oils without surfactants (e.g. tri-, di- 
and monoglycerides) 
Oils and water-
insoluble surfactants 
Oils, surfactants and 
cosolvents (both water-
insoluble and water-
soluble excipients) 
Water-soluble 
surfactants and 
cosolvents (no oils) 
Properties Nondispersing, requires digestion 
SNEDDS formed 
without water-soluble 
components 
SNEDDS/SMEDDS 
formed with water-
soluble components 
Formulation disperses 
typically to form a 
micellar solution 
Pros 
GRAS status;  simple;  excellent 
capsule compatibility 
Unlikely to lose 
solvent capacity on 
dispersion 
Clear or almost clear 
dispersion; drug 
absorption without 
digestion 
Formulation has good 
solvent capacity for 
many drugs 
Cons 
Formulation has poor solvent 
capacity unless drug is highly 
lipophilic 
Turbid o/w dispersion 
(particle  size 0.25–2 
µm) 
Possible loss of solvent 
capacity on dispersion;  
less easily digested 
Likely loss of solvent 
capacity on dispersion; 
might not be digestible 
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2. Formulation excipients 
2.1 Lipids (Chakraborty, Shukla, Mishra, & Singh, 2009) 
The lipid is a importance component in the formulation of SNEDDS as physicochemical 
properties of oil (e.g., molecular volume, polarity and viscosity) significantly affect the 
spontaneity of the nanoemulsification process, droplet size of the nanoemulsion and drug 
solubility. Not only can lipids solubilize marked amounts of lipophilic drugs and 
facilitate self- emulsification, but they also have the propensity to augment the fraction of 
drug transported via intestinal lymphatic system, thereby increasing its absorption from 
the GI tract. Natural edible oils, comprised of medium-chain triglycerides are not usually 
used owing to their poor ability to dissolve large amounts of lipophilic drugs. Modified 
long- and medium-chain triglyceride oils, with varying degrees of saturation or 
hydrolysis, have widely been used for the design and development of SNEDDS 
formulations. These oils offer distinct formulative and physiological advantages, as their 
degradation products resemble that of the natural end-products of intestinal digestion. 
Both unsaturated and saturated fatty acids have been widely employed in the formulation 
of lipidic systems. However, the SNEDDS in particular are comprised of saturated fatty 
acids such as caproic, caprylic, capric, lauric, and myristic acid.(M.-L. Chen, 2008) One 
can make the appropriate choice of these by examining their composition, potential 
utilities, physical state, and hydrophilic-lipophilic balance (HLB). Given table provides a 
comprehensive account of most of such lipidic constituents, along with their 
characteristics. These amphiphilic excipients are progressively and effectively replacing 
the conventional (i.e., natural) medium-chain triglyceride oils in SNEDDS systems. 
2.2 Surfactant (Bouchemal, Briançon, Perrier, & Fessi, 2004) 
Second to the oils, the other most vital component of the SNEDDS is an emulsifier or a 
surfactant. The selection of surfactant is also critical process for the formulation of 
SNEDDS. The characteristic of the surfactant, such as HLB (in oil), cloud point, 
viscosity and affinity for the oily phase, have great influence on the nanoemulsification 
process, self-nanoemulsification region and the droplet size of nanoemulsion. An 
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emulsifier, invariably a surfactant, is obligatory to provide the essential emulsifying 
characteristics. Surfactants, being amphiphilic in nature, can dissolve (or solubilize) 
relatively high amounts of hydrophobic drug compounds. Emulsifiers from natural 
sources are regarded as much safer than synthetic ones. However, as the former possess 
only limited self-emulsification capacities, these are seldom employed for the 
formulation of SNEDDS. The twin issues that govern the selection of a surfactant are its 
HLB and safety. The HLB of a surfactant provides important information on its potential 
utility in the formation of SNEDDS. For imparting high self-emulsifying properties to the 
SNEDDS formulation, the emulsifier should have a relatively high HLB (i.e., high 
hydrophilicity) for immediate formation of o/w droplets, and/or rapid spreading of the 
formulation in the aqueous media. The most widely recommended emulsifiers, which 
include nonionic surfactants with relatively high HLB values such as solid or liquid 
ethoxylated polyglycolyzed glycerides, polyoxyethylene (20) sorbitan monooleate (i.e., 
Tween 80), and poly(ethylene oxide)- poly(propylene oxide), block copolymers such as 
Pluronic F127. Because at times, high amounts of hydrophobic drugs need to be 
dissolved, the formulation of an effective SNEDDS usually requires quite high 
concentrations of an emulsifying surfactant. For forming stable SNEDDS, the surfactant 
concentration usually should range between 30% and 60% w/w, as higher concentrations 
may be irritating to the GI mucosa. 
2.3 Co-solvents (Biradar, Dhumal, & Paradkar, 2009b) 
Co-solvents, such as ethanol, propylene glycol, and PEG, are also commonly required to 
enable the dissolution of a large quantity of hydrophilic surfactant(s) in SNEDDS. Lipid 
mixtures with higher surfactant/oil or co-surfactant/oil ratios lead to the formation of 
SNEDDS. However, co-solvents have a serious limitation of becoming evaporated from 
the shells of sealed gelatin capsules, leading eventually to the precipitation of drug inside 
the shell. Newer co-solvents such as Transcutol and Glycofurol have several stellar 
advantages over traditional ones, including better stability and less volatility. 
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3. Method of preparation (Nicolas  Anton & Vandamme, 2009; Bouchemal et al., 2004; 
Vyas, Shahiwala, & Amiji, 2008) 
The methods for preparation of the nanoemulsions are classified into high-energy 
emulsification methods or low-energy emulsification methods.  
1. High energy emulsification 
High Pressure Homogenization 
Microfluidization 
Ultrasonic emulsification 
 
2. Low energy emulsification 
Phase inversion temperature 
Solvent displacement method 
Self emulsification system. 
 
 In high-pressure homogenization, the coarse macroemulsion is passed through a small 
orifice at an operating pressure in the range of 500 to 5000 psi. The nanoemulsions with 
desired size range and dispersity can be obtained by varying the operating pressure and 
the number of passes through interaction chambers like high-pressure homogenization.  
Microfluidization is a mixing technique, which makes use of a device called 
microfluidizer. This device uses a high-pressure positive displacement pump (500 to 
20000psi), which forces the product through the interaction chamber, which consists of 
small channels called ‘microchannels’. The product flows through the microchannels on 
to an impingement area resulting in very fine particles of sub- micron range. 
Ultrasonic emulsification uses a probe that emits ultrasonic waves to disintegrate the 
macroemulsion by means of cavitation forces. By varying the ultrasonic energy input and 
time, the nanoemulsions with desired properties can be obtained. 
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The phase inversion temperature (PIT) method as an alternative to high shear 
emulsification. In the PIT method, oil, water and nonionic surfactants are mixed together 
at room temperature and the mixture typically comprises O/W microemulsions coexisting 
with excess oil, and the surfactant. When this macroemulsion is heated gradually, the 
surfactant becomes lipophilic and at higher temperatures, the surfactant gets completely 
solubilized in the oily phase and the initial O/W emulsion undergoes phase inversion to 
W/O emulsion.(Shafiq et al., 2007) 
In solvent displacement method, oily phase is dissolved in water-miscible organic 
solvents. The organic phase is poured into an aqueous phase containing surfactant to 
yield spontaneous nanoemulsion by rapid diffusion of organic solvent. The organic 
solvent is removed from the nanoemulsion by a suitable means, such as vacuum 
evaporation (Trimaille et al., 2001). 
Self emulsification (B. Singh et al., 2009) 
The mechanism through which self-emulsification occurs has not yet been thoroughly 
elucidated. Nevertheless, it has been suggested that self-emulsification takes place when 
the entropy change favoring dispersion is greater than the energy required to increase the 
surface area of the dispersion. The free energy of a conventional emulsion formulation is 
a direct function of the energy required to create a new surface between the oil and water 
phases. The thermodynamic relationship for the net free energy change is described by 
following equation. 
               
   ... ... ... (1) 
where ΔG is the free energy associated with the process, ri is the radius of the droplets, Ni 
is the number of droplets, and σ is the interfacial energy. The two phases of the emulsion 
tend to separate with time to reduce the interfacial area and thus minimize the free energy 
of the system(s). Conventional emulsifying agents stabilize emulsions resulting from 
aqueous dilution by forming a monolayer around the emulsion droplets, reducing the 
interfacial energy and forming a barrier to coalescence. On the other hand, emulsification 
occurs spontaneously with SNEDDS, as the free energy required to form the emulsion is 
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low, whether positive or negative. For emulsification to take place, it is vital for the 
interfacial structure to offer negligible or no resistance against surface shearing. The ease 
of emulsification has been suggested to be related to the ease of water penetration into 
various liquid crystals or gel phases formed on the surface of the droplet. The interface 
between the oil and aqueous continuous phases is formed upon addition of a binary 
mixture (oil/ non-ionic surfactant) to water. This is followed by solubilization within the 
oil phase as a result of aqueous penetration through the interface. This occurs until the 
solubilization limit is attained close to the interphase. Further, aqueous penetration will 
lead to the formation of the dispersed liquid crystal phase. Ultimately, everything that is 
in close proximity to the interface will be liquid crystal, the actual amount of which 
depends upon the emulsifier concentration in the binary mixture. Therefore, following 
gentle agitation of the self-emulsifying system, water rapidly penetrates into the aqueous 
cores, leading to interface disruption and droplet formation. As a result of the liquid 
crystal interface formation surrounding the oil droplets, the SNEDDS become quite stable 
to coalescence. Moreover, the presence of the drug compound may alter the emulsion 
characteristics, possibly by interacting with the liquid crystal phase. Nevertheless, the 
correlation between liquid crystal formation and spontaneous emulsification has still not 
been properly established. 
4. Absorption of drug (Pouton, 1997; Sripriya Venkata Ramana Rao, Yajurvedi, & 
Shao, 2008) 
Most of the dietary lipids are triglycerides which are fatty acids ester of glycerol, on 
ingestion of the triglycerides a coarse emulsion is believed to form in stomach with 
dietary phospholipids, proteins and polysaccharides are believed to be potent emulsifiers, 
forming a monolayer around the triglyceride droplets. Around 10 to 40% of normal fat 
digestion takes place in the stomach, involving hydrolysis to diglycerides and fatty acids. 
This process is being done by human gastric lipase (HGL). Short chain fatty acids may 
dissolve into the aqueous phase followed by absorption across the stomach mucosa, while 
longer chain acids may remain incorporated in the emulsion droplet core. The emulsion 
passes to the upper section of the large intestine where particle size reduction of the 
droplets takes place due to the presence of a range of emulsifying agent including bile 
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salts, monoglycerides, cholesterol, lecithin and lysolecithin, yielding an approximate size 
range of 0.5 to 1 μm. The mechanism responsible for such efficient emulsification of 
ingested triglycerides are not yet clear, although in vitro studies have shown that mono 
olein, oleic acid and monomeric bile salts may at intestinal pH significantantly lower the 
interfacial tension of triolein droplets there by allowing emulsification to take place under 
condition of comparatively low shear. Then lypolysis takes place via triacylglycerol acyl 
hydrolase, typically referred to as pancreatic lipase. This enzyme act specifically at the 
surface of emulsion droplets and causes hydrolysis of triglyceride at the 1
st
 and 3
rd
 
position to produce fatty acids, diglycerides and monoglycerides. 
5. In vitro characterization of self- nanoemulsifving drug deliverv svstems 
5.1 Equilibrium Phase Behavior (Ehab I.  Taha, Al-Saidan, Samy, & Khan, 2004) 
Although self-emulsification is a dynamic, non-equilibrium process involving interfacial 
phenomena, the information about the process can be obtained using equilibrium-phase 
behavior. There appears to be a correlation between emulsification efficiency and the 
region of enhanced water solubilization (i.e., a typical characteristic of nonionic 
surfactant system) and phase inversion region and the formation of lamellar liquid 
crystalline dispersion phase on further incorporation of water. This method also allows 
comparison among different surfactants and their synergy with the chosen co-solvent(s) 
or co-surfactant(s). The boundaries of the monophasic region can be easily demarcated 
by visual observation of the samples. Phase behavior of the three component system can 
be represented pictorially by a ternary phase diagram, which can be computed manually 
or derived using software. 
 
5.2 Spontaneity of self emulsification  
Spontaneity or the rate of self-emulsification can be assessed by visual inspection or by 
monitoring the turbidity change of the dispersion by appropriate instrumental method. 
The self-emulsifying formulation is added to a known volume of water at room 
temperature under gentle agitation. The ease of emulsion formation is observed and 
termed as "good," when the emulsion formation is spontaneous and the formulation 
spreads into a uniform fine emulsion, or "bad," when poor or no emulsion is formed and 
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an immediate coalescence of the droplets is observed (A.A. Date & Nagarsenker, 2007). 
The spontaneity of emulsion formation is also observed by injecting the formulation into 
a flowing stream of water and measuring the change in turbidity with time (Zidan et al., 
2007). 
 
5.3 Droplet size analysis 
Droplet size distribution is one of the important physicochemical measurement parameter 
of a nano-emulsion, and is measured by a diffusion method using a light-scattering 
particle size analyzer. Many other techniques that have been developed to measure 
droplet size of nanoemulsions, like laser light scattering (LLS) and energy filtering 
transmission electron microscopy (EFTEM) (Dabhi, Limbani, & Sheth, 2011). 
Morphology and structure of the nanoemulsion could be studied using transmission 
electron microscopy. Combination of bright field imaging at increasing magnification 
and of diffraction modes was used to reveal the form and size of nanoemulsion droplets. 
Observations was performed as, a drop of the nanoemulsion was directly deposited on the 
holey film grid and observed after drying. The average diameters and polydispersity 
index of nanoemulsion cna measured by photon correlation spectroscopy 
 
5.4 Viscosity determination (Biradar, Dhumal, & Paradkar, 2009a) 
Viscosity is a measure of the resistance of a fluid which is being deformed by either shear 
or tensile stress. In everyday terms (and for fluids only), viscosity is "thickness" or 
"internal friction". Viscosity may affect in different way like duting the filling in the 
capsule, converting the SNEDDS in to solid form etc. So, it must be determined for the 
formulation. Viscosity is measured with various types of viscometers and rheometers. A 
rheometer is used for those fluids which cannot be defined by a single value of viscosity 
and therefore require more parameters to be set and measured than is the case for a 
viscometer. Close temperature control of the fluid is essential to accurate measurements, 
particularly in materials like lubricants, whose viscosity can double with a change of only 
5°C.  
 
5.5 Drug content  
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Drug from pre-weighed SNEDDS is extracted by dissolving in suitable solvent. Drug 
content in the solvent extract was analyzed by suitable analytical method against the 
standard solvent solution drug. 
 
5.6 Zeta potential 
The particle charge is of importance in the study of the stability of the nanoemulsion. 
Zeta potential is used to determine the charge at droplet surface. Particle charge is 
measured by electrophoresis and expressed as electrophoretic mobility [(µm/S) /(V/cm)] 
or converted to the zeta potential (mV). Usually the zeta potential of more than ±40mV 
will be considered to be required for the stabilisation of the dispersions. Minimum 
±30mV zeta potential is required for electrostatically stable suspension and in case of 
combined steric and electrostatic stabilization it should be a minimum of ±20mV of zeta 
potential is required (Peltonen & Hirvonen, 2010). 
 
5.7 Thermodynamic stability studies  
The physical stability of a lipid based formulation is also crucial to its performance, 
which can be adversely affected by precipitation of the drug in the excipient matrix. In 
addition, poor formulation physical stability can lead to phase separation of the excipient, 
affecting not only formulation performance, but visual appearance as well.  
• Heating cooling cycle: six cycles between refrigerator temperature (40C) and 450C with 
storage at each temperature of not less than 48 hrs is studied. Those formulations, which 
are stable at these tem-peratures, are subjected to centrifugation test.  
• Centrifugation: Passed formulations are centrifuged thaw cycles between 210C and 
+25
0
C with storage at each temperature for not less than 48 hrs is done at 3500 rpm for 
30 min. Those formulations that does not show any phase separation are taken for the 
freeze thaw stress test.  
• Freeze thaw test: Three freeze for the formulations. Those formulations passed this test 
showed good stability with no phase separation, creaming, or cracking.  
 
5.8 Percentage transmittance 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 18
Introduction 2 
 
 
Percentage transmittance of the prepared nanoemulsion formulations are determined to 
have an insight into the spontaneity of emulsions formation. It could be measured by 
spectrophotometric technique. 
 
5.9 In vitro drug release 
The drug dissolution testing is routinely used to provide critical in vitro drug release 
information. The dissolution of most commonly dosage form performed by USP 
dissolution apparatus I/II and drug release is estimated using HPLC-UV visible 
Spectrophotometry. 
 
6. Application of SNEDDS as different dosage form 
The SNEDDS have been formulated as different dosage forms such as Dry Emulsions: 
(Kohli, Chopra, & Dhar, 2010), Capsules: (Palamakula, Nutan, & Khan, 2004), Tablets, 
Pellets: (Z. Wang et al., 2010), Nanoparticles, Suppositories, Implants
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7. Various marketed formulation of SNEDDS 
Table 2.2. Marketed formulations of SNEDDs 
 
8. Conclusion:  
From the literature survey done on the various formulation, development and characterization 
of self nanoemulsifying systems, it could be concluded that SNEDDS could be employed  for 
improving dissolution characteristics of anti diabetic drugs of sulfonylurea class. Hence it 
was decided that self nanoemulsifying drug delivery strategy would be employed for 
improving the dissolution characteristics of selected drugs from sulfonylurea class. 
Drug Name  Compound  Dosage form  Company  Indication  
Agenerase®  Amprenavir  
Soft gelatin 
capsule  Glaxo Smithkline  HIV antiviral  
Targretin®  Bexarotene  
Soft gelatin 
capsule  Ligand  Antineoplastic  
Rocaltrol®  Calcitriol  
Soft gelatin 
capsule  Roche  Calcium regulator  
Neoral®  
Cyclosporine 
A/I  
Soft gelatin 
capsule  Novartis  Immune suppressant  
Sandimmune®  
Cyclosporine 
A/II  
Soft gelatin 
capsule  Novartis  Immuno Suppressant  
Gengraf®  
Cyclosporine 
A/III  
Hard gelatin 
Capsule  Abbott Laboratories  Immuno suppressant  
Lipirex®  Fenofibrate  
Hard gelatin 
Capsule  Genus  
Antihyper-
lipoproteinemic  
Norvir®  Ritonavir  
Soft gelatin 
capsule  Abbott Laboratories  HIV antiviral  
Fortovase®  Saquinavir  
Soft gelatin 
capsule  
Hoffmann-La Roche 
inc.  HIV antiviral  
Convulex®  Valproic acid  
Soft gelatin 
capsule  Pharmacia  Antiepileptic  
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1. Introduction 
 
The basic challenge faced by the researcher for the formulation of poorly soluble drugs is 
the low oral bioavailability and erratic absorption of the drugs from the gastrointestinal 
tract due to their low saturation solubility and dissolution velocity. The low saturation 
solubility results in a low concentration gradient between the gut and blood vessel and 
leads to a limited transport of drug  (Gao, Zhang, & Chen, 2008).
 
For poorly soluble 
drugs as seen in BCS Class II, the dissolution of the drugs in the gastrointestinal fluid 
media is the rate limiting step for the absorption of the drugs (Mu¨ller, Jacobs, & Kayser, 
2001).
 
Hence for efficient absorption of drugs from the gastrointestinal tract for 
improving their therapeutic efficacy, there is an imminent need for studies in designing 
novel strategies for their dissolution enhancement. 
There are number of formulation approaches viz., salt formation, pH adjustment, 
cosolvency, complexation, etc (Rabinow, 2004) used for enhancement of dissolution but 
none of the approach has achieved the merits of being universal. However, there are 
several disadvantages associated with these approaches. For example, the alteration of 
chemical structure by forming water-soluble derivatives often requires long processing 
times at a very expensive cost to derive the new chemical entities (NCEs) (Venkatesh & 
Lipper, 2000). The use of solubilizing excipients is often limited by their toxicity. For 
example, the nonionic surfactant polyoxyethylated castor oil (Cremophor EL) has been 
shown to cause nephrotoxicity, hypersensitivity reactions and lowering of the white blood 
cell count (neutropenia). Micronization of poorly soluble drugs has been applied for 
many years to improve dissolution velocity of poorly soluble drugs but reducing the drug 
to micron size does not increase the saturation solubility of the drug, and at such a low 
saturation solubility, as generally observed in BCS Class II drug, the increment in the 
dissolution characteristics does not help to a great extent (Abhijit A.  Date & Patravale, 
2004; Patravale, Date, & Kulkarni, 2004). Consequently off late nanonisation has been 
employed for treating the BCS Class II drugs. When the drug is being reduced to 
nanosized level there is an obvious increase in its saturation solubility assisted by 
improvement in the dissolution characteristics which could be attributed to the effective 
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increase in particle surface area according to the Nernst Brunner-Noyes Whitney 
equation (Shah, Shah, Patel, & Potdar, 2012). 
As per FDA a nanoparticulate drug is not considered as “generic” to an approved product 
and therefore can be patented; and are considered as “newdrug”, because nanoparticulate 
drug is not bioequivalent to a microcrystalline or solubilized form of the same drug, 
administered at the same dosage. It also offers a unique advantage to pharmaceutical 
companies of product line extension for the existing drug formulations (Singare et al., 
2010). The nanotechnology is currently gaining attention from researchers and 
pharmaceutical industry. In the pharmaceutical field, the term “nanoparticle” is generally 
used to describe submicron sized particles(Brannon-Peppas & Blanchette, 2004; 
Kawashima, 2001). The drug of interest is dissolved, entrapped or encapsulated within 
the particles. Nanoparticle technologies have been used as important strategies to deliver 
drugs, including peptides and proteins, vaccines and more recently nucleotides. In 
pharmaceutical field nanotechnology covered the area like nanosuspension, 
nanoemulsion, self nanoemulsifying drug delivery system, solid lipid nanoparticle(SLN) 
etc. A nanosuspension consists of drug nanocrystals, stabilizing agents, typically 
surfactants or polymeric stabilizers, and a liquid dispersion medium (Patravale et al., 
2004). Drug nanocrystals are pure solid drug particles with a mean particle size below 1 
μm, generally between 200 nm and 500 nm (Keck & Müller, 2006). Although the term 
nanocrystals implicates a crystalline structure, the particles can be crystalline, partially 
crystalline or completely amorphous. The dispersion medium can be water, mixtures of 
water with other non-aqueous media or non-aqueous media. Nanosuspension permit 
delivery of drugs that are poorly soluble in water or unstable in biological fluids. 
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2. Method of preparation 
Nanosuspensions can be prepared using various techniques, which could be classified 
broadly in two groups based on the principle on which the nanosize is achieved. Top 
down production, in which the drug macrosuspension is size reduced to nanosuspension 
and secondly bottom up method in which the drug nanoparticles are assembled from a 
solution of drug by controlling the rate and growth of nuclei formed. 
The bottom up method consists of 
Nanoprecipitation 
Supercritical fluid technology 
Using emulsions and microemulsions as templates. 
The top down method consists of 
Media Milling 
Dry Cogrinding 
High Pressure homogenization 
The method employed herein are discussed in detail. 
Nanoprecipitation (Dong, Ng, Shen, Kim, & Tan, 2011; Gao et al., 2008; Kakran, 
Sahoo, Lia, & Judeh, 2010) 
In the precipitation technique the poorly water-soluble drug is dissolved in a suitable 
solvent and the solution is added into a miscible anti-solvent with stirring and agitation.  
Stabilizers are used to avoid the spontaneous aggregation of molecules.  Types of 
solvents, the volume ratio of antisolvent to solvent, stirring rate, drug content etc are the 
factors which affect the final morphology of nanoparticles. 
The precipitation process involves nucleation and crystal (particles) growth of drug 
particles from a supersaturated solution. The supersaturated solution is a solution in 
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which the concentration of solute exceeds the saturation or equilibrium solute 
concentration at a given temperature. Thus, a supersaturated solution is not at 
equilibrium, and crystallization of the solute occurs in order to move the solution towards 
equilibrium. After initial particle nucleation, both nucleation and crystal growth attempt 
to bring the supersaturated solution to equilibrium. The time required for crystallization 
depends on the driving force of supersaturation. 
The nucleation rate increases with increasing temperature and degree of supersaturation, 
but decreases with increasing surface energy. High nucleation rates offer the potential to 
produce a large number of submicron particles in the final dispersion, as long as the 
growth can be arrested by stabilizers. Precipitation technologies are used in both the 
chemical and pharmaceutical industries for the production of nanoparticles. The usual 
precipitation technologies, including solvent evaporation and salting out, have in 
common the disadvantages of poor control over particle morphology and particle size and 
size distribution producing a wide range of particle sizes. 
Precipitation has also been coupled with high shear processing. The NANOEDGE 
process (is a registered trademark of Baxter International Inc. and its subsidiaries) relies 
on the precipitation of friable materials for subsequent fragmentation under conditions of 
high shear and/or thermal energy (Zili, Sfar, & Fessi, 2005). This is accomplished by a 
combination of rapid precipitation and high-pressure homogenization. Rapid addition of a 
drug solution to an antisolvent leads to sudden supersaturation of the mixed solution, and 
generation of fine crystalline or amorphous solids. Precipitation of an amorphous material 
may be favored at high supersaturation when the solubility of the amorphous state is 
exceeded. The success of drug nanosuspensions prepared by precipitation techniques has 
been extensively reported (X. Chen, Young, Sarkari, Williams III, & Johnston, 2002; Cho 
et al., 2010; Kipp, Wong, Doty, & Rebbeck, 2004). 
Advantage: It is simple process, low cost equipment, ease of scale up 
Disadvantage: Drug has to soluble at least in one solvent and that this solvent needs to be 
miscible with a non-solvent, growing of drug crystals needs to be limit by surfactant 
addition. 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 24
Introduction 2 
 
 
Media Milling 
The pearl milling technique is developed by Liversidge et al.(G. G. Liversidge & 
Conzentino, 1995) Wet milling is a particle size reduction technology whereby drug 
crystals are comminuted using high-shear media mills in the presence of surface 
stabilizer(s) and grinding media (Gao et al., 2008; Niwa, Miura, & Danjo, 2011). In 
media milling technique the drug is milled with milling media in simple glass vials to 
specific milling chambers for certain hours to some days and nanosuspensions are 
produced on a principle of high energy and shear forces generated as a result of the 
impaction of the milling media with the drug. The media like zirconium oxide beads, 
highly cross-linked polystyrene resin beads, glass beads are used. A problem associated 
with the media milling technology is the erosion from the milling material during the 
milling process. In order to reduce the quantity of impurities caused by an erosion of the 
milling media, the milling beads are coated with highly cross-linked polystyrene resin. A 
continuous problem is the adherence of product to the large inner surface area of the 
milling system. The inner surface area is made up of the surface area of the chamber and 
of all milling beads together. Even in recirculation systems, this product adherence causes 
a product loss. Of course, this undesirable drug loss can be an issue in very costly drugs. 
The level and type of stabilizer are important parameters to achieve nanoparticle size 
using this technology. The sizes of beads, number of beads, milling time, milling speed, 
characteristics of drug, temperature are the factors affecting the final product.  By using 
this technique Rapamune was launched by Wyeth as the first product containing 
Sirolimus NanoCrystals. The coated Rapamune tablets are more convenient and show a 
27% increased bioavailability compared to the Rapamune® solution. This is an example 
to increasing dissolution rate by using nanonization. 
 
Advantage: It includes ease of scale up, little batch to batch variation, high flexibility in 
handling large quantities of drugs. 
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Disadvantage includes -Generation of residue of milling media, requires milling process 
for hours to days, prolonged milling may induce the formation of amorphous lead to 
instability 
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3. Theoretical aspects 
Increasing saturation solubility and dissolution velocity 
Classically saturation solubility in a given solvent is defined as a compound-specific 
constant depending only on the temperature however the saturation solubility is also a 
function of the crystalline structure (i.e. lattice energy) and particle size. In general, 
solubility is best for the polymorphic modification that is characterized by highest energy 
and lowest melting point. The reason why saturation solubility is also a function of 
particle size can be explained by the Kelvin and the Ostwald–Freundlich equation as 
shown in equation (1) 
  
  
  
 
    
    
 
   ... ... ... (1) 
where Pr is the dissolution pressure of a particle with the radius r, P∞ is the dissolution 
pressure of an infinitely large particle, γ is the surface tension, R is the gas constant, T is 
the absolute temperature, r is the radius of the particle, Mr is the molecular weight, and ρ 
is the density of the particle. According to the Kevin equation, the dissolution pressure 
increases with increasing curvature, which means decreasing particle size. The curvature 
is enormous when the particle size is in the nanometer range; then a large dissolution 
pressure can be achieved leading to a shift of the equilibrium toward dissolution. The 
Ostwald–Freundlich  directly describes the relation between the saturation solubility of 
the drug and the particle size as shown in equation (2)  
   
  
  
 
   
         
 
         ... ... ...
 (2) 
where CS is the saturation solubility, Cα is the solubility of the solid consisting of large 
particles, σ is the interfacial tension of substance, V is the molar volume of the particle 
material, R is the gas constant, T is the absolute temperature, ρ is the density of the solid, 
and r is the radius. It is obvious that the saturation solubility (Cs) of the drug increases 
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with a decrease of particle size (r). However, this effect is pronounced for materials that 
have mean particle size of less than 2 µm. The increase of nanocrystals in the dissolution 
velocity can be explained by the Noyes–Whitney equation. For drug nanocrystals, the 
increased saturation solubility (CS) and surface area (A) lead to an increase in the 
dissolution velocity (dX/dt) as shown in equation (3) 
  
  
 
  
  
           
  ... ... ... (3) 
where dX/dt is the dissolution velocity, D is the diffusion coefficient, A is the surface 
area, hD is the diffusional distance, CS is the saturation solubility, and Ct is the 
concentration around the particles. Another important factor is the diffusional distance 
hD, which, as a part of the hydrodynamic boundary layer hH, is also strongly dependent 
on the particle size, as the Prandtl equation shown in equation (4) (Mosharraf and 
Nystrom 1995): 
                    
 ... ... ... (4) 
where hH is the hydrodynamic boundary layer, k denotes a constant, L is the length of the 
particle surface, and V is the relative velocity of the flowing liquid surrounding the 
particle. 
According to the Prandtl equation, the reduced particle size leads to a decreased 
diffusional distance hD and consequently an increased dissolution velocity, as described 
by the Noyes–Whitney equation. Therefore, to sum up, a reduction in the drug particle 
size in the nanometer range leads to an increase in solubility as well as the dissolution 
velocity. Both are very important factors with regard to the aim of improving the 
bioavailability of poorly soluble drugs. 
Another special feature of nanosuspensions is the absence of Ostwald ripening meaning 
physical long-term stability as an aqueous suspension 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 28
Introduction 2 
 
 
Ostwald ripening has been described for highly dispersed systems, which means a 
reduction in size of the finest particle fraction and their final disappearance combined 
with simultaneously growth of the larger particles. Reasons for the Ostwald ripening are 
the different saturation solubilities in the vicinity of differently sized particles and the 
concentration gradient existing between them. Molecules from the higher concentrated 
solution around very small particles diffuse to the vicinity of larger particles where a 
lower concentration is present. This leads to supersaturation and drug crystallization, 
which means growth of the larger particles. Simultaneously the vicinity of smaller 
particles will be below the saturation concentration, thus the new drug will be dissolved 
and the fine particles are getting smaller. This is a continuous process finally leading to 
the disappearance of the fine particles. The lack of Ostwald ripening in nanosuspensions 
is attributed to the uniform particle size created by the homogenization process. The 
differences in saturation solubility in combination with the a priori low solubility of the 
poorly soluble drug keeps the concentration differences sufficiently low to avoid the 
ripening effect. 
4. Evaluation parameters 
4.1 Shape, size and size distribution 
Structural characterization like shape, size, surface morphology, size distribution, etc is a 
parameter that plays important role in determining various attributes of a nanosystem. 
The shape of the nanosuspension can be determined using a transmission electron 
microscope (TEM) and/or a scanning electron microscope (SEM).
 
Size and size 
distribution are the most important parameter in the evaluation of the suspensions as it is 
having the direct effects on saturation solubility and dissolution velocity, physical 
stability of drugs. The mean particle size and the width of particle size distribution i.e. 
polydispersity index (PI) are determined by Photon Correlation Spectroscopy (PCS). PI 
governs the physical stability of nanosuspension and should be as low as possible for 
long-term stability (Should be close to zero). A PI value of 0.1–0.25 indicates a fairly 
narrow size distribution whereas a PI value greater than 0.5 indicates a very broad 
distribution. However, due to a narrow measuring range of PCS, approximately from 3 
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nm to 3 µm,  laser diffractometry (LD) is needed to study the content of particles in the 
micrometer range of approximately 0.05–80 µm up to a maximum of 2000 µm, 
depending on the type of equipment used. 
4.2 Particle charge (zeta Potential) 
The particle charge is of importance in the study of the stability of the suspensions. Zeta 
potential is used to determine the charge at particle surface. Particle charge is measured 
by electrophoresis and expressed as electrophoretic mobility [(µm/S) /(V/cm)] or 
converted to the zeta potential (mV). Usually the zeta potential of more than ±40mV will 
be considered to be required for the stabilization of the dispersions. Minimum ±30mV 
zeta potential is required for electrostatically stable suspension and in case of combined 
steric and electrostatic stabilization it should be a minimum of ±20mV of zeta potential is 
required (Gao et al., 2008). 
4.3 Crystalline status 
The evaluation of crystalline state is necessary in case of drug exists in different 
polymorphic forms. When nanosuspensions are prepared drug particles may get 
converted to amorphous form hence it is essential to measure the extent of amorphous 
drug generated during the production of nanosuspensions. Differential scanning 
calorimetry (DSC) and X-ray diffraction can be used to evaluate the crystalline structure 
of the drug nanosuspension. 
4.4 Dissolution velocity and saturation solubility 
The main advantage associated with the nanosuspensions is improved saturation 
solubility as well as dissolution velocity. Measurement of the saturation solubility and 
dissolution velocity is very important parameter which help to measure the benefits 
compared to the conventional or microparticle formulation. Dissolution velocity is 
measured by the method given in pharmacopoeia. Saturation solubility is measured by 
shaking the drug in different solvent at different temperature up to equilibrium 
4.5 Stability of nanosuspensions 
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Stability of the suspensions is dependent on the particle size. As the particle size reduces 
to the nanosize the surface energy of the particles will be increased and they tend to 
agglomerate. So stabilizers are used which will decrease the chances of Ostwald ripening 
and improving the stability of the suspension by providing a steric or ionic barrier. 
4.6 In vivo evaluation 
The in vivo evaluation of the nanosuspensions is specific to drug and route of 
administration. Most commonly the formulation was given by required route of 
administration and the plasma drug levels were estimated using HPLC-UV visible 
Spectrophotometry. Other parameters which are generally evaluated in vivo are surface 
hydrophilicity/hydrophobicity (determines interaction with cells prior to phagocytosis), 
adhesion properties, interaction with body proteins etc. 
4.7 In vitro drug release 
The drug dissolution testing is routinely used to provide critical in vitro drug release 
information. The dissolution of most commonly dosage form performed by USP 
dissolution apparatus I/II and drug release is estimated using HPLC-UV visible 
Spectrophotometry. 
5. Application of nanosuspension in different dosage form 
Formulating the drug as nanosuspensions increases the saturation solubility, dissolution 
velocity as well as bioavailability of the drug. From the formulation point of view, 
nanosuspensions meet almost all the needs of an ideal drug delivery system for the 
parenteral route. These nanosuspensions are having application in different routes of 
administrations like oral, parenteral, topical, ophthalmic, mucoadhesive, pulmonary and 
targeted drug delivery. The administration of nanosuspensions is a drug delivery strategy, 
not only to improve bioavailability, but also to reduce the amount of those drugs used, to 
localize the delivery of potent compounds and, therefore, to reduce side effects. 
6. Marketed formulations of nanosuspensions 
Table 2.3 Marketed formulations of nanosuspensions 
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Drug Indication Route Marketed Company 
Abraxane
®
 (paclitaxel) Anti-cancer I.V. 2005 
Abraxis Bioscience/ 
Astrazeneca 
Emend
®
 (aprepitant) Anti-emetic Oral 2003 Merck/Elan 
Megace ES
®
 (megesterol 
acetate) 
Eating disorders Oral 2005 Par/Elan 
Rapamune
®
 (sirolimus) 
Immuno-
suppresant 
Oral 2001 Wyeth/Elan 
Tricor
®
 (fenofibrate) Lipid regulation Oral 2004 Abbott/Elan 
Triglide
®
 (fenofibrate) Lipid regulation Oral 2005 
Sciele Pharma/ 
Skyepharma 
7. Conclusion 
From the literature survey done on the various formulation, development and 
characterization of nanosuspensions, it could be concluded that nanosuspension approach 
could be employed for improving dissolution characteristics of anti diabetic drugs of 
sulfonylurea class. Hence it was decided that nanosuspensions of selected drug from 
sulfonylurea class would be prepared for improving their dissolution characteristics. Two 
basic approaches were selected for preparing nanosuspensions viz., media milling and 
liquid anti solvent precipitation. 
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2.4 Polymers 
2.4.1 Hydroxy propyl methyl cellulose 
It is partly  O-methylated and O-(2-hydroxypropylated) cellulose. It is available in 
several grades that vary in viscosity and extent of substitution. Grades may be 
distinguished by appending a number indicative of the apparent viscosity.  
Functional Category  
Bioadhesive material; coating agent; controlled-release agent; dispersing agent; 
dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; 
film-forming agent; foaming agent; granulation aid; modified-release agent; 
mucoadhesive; release-modifying agent; solubilizing agent; stabilizing agent; suspending 
agent; sustained-release agent; tablet binder; thickening agent; viscosity-increasing agent. 
Regulatory Status 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA 
Inactive Ingredients Database 
 
Figure 2.2 Hydroxy propyl methyl cellulose 
2.4.2 Hydroxy ethyl cellulose 
Hydroxyethyl cellulose is a partially substituted poly(hydroxyethyl) ether of cellulose. 
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It is available in several grades that vary in viscosity and degree of substitution; some 
grades are modified to improve their dispersion in water. The grades are distinguished by 
appending a number indicative of the apparent viscosity 
Functional Category 
Coating agent; suspending agent; tablet binder; thickening agent; viscosity-increasing 
agent. 
Regulatory Status 
Included in the FDA Inactive Ingredients Database 
 
Figure 2.3 Hydroxy ethyl cellulose 
2.4.3 Hydroxy propyl cellulose 
Hydroxypropyl cellulose is a partially substituted poly(hydroxypropyl) ether of cellulose. 
It may contain no more than 0.6% of silica or another suitable anticaking agent. 
Hydroxypropyl cellulose is commercially available in a number of different grades that 
have various solution viscosities. 
Functional Category 
Coating agent; emulsifying agent; stabilizing agent; suspending agent; tablet binder; 
thickening agent; viscosity-increasing agent  
Regulatory Status 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA 
Inactive Ingredients Database 
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Figure 2.4.Hydroxy propyl cellulose 
 
2.4.4 Poloxamer 
The poloxamer polyols are a series of closely related block copolymers of ethylene oxide 
and propylene oxide conforming to the general formula 
HO(C2H4O)a(C3H6O)b(C2H4O)aH.  
Functional Category 
Dispersing agent; emulsifying agent; solubilizing agent; tablet lubricant; wetting agent. 
Regulatory Status 
Included in the FDA Inactive Ingredients Database (IV injections; inhalations, 
ophthalmic preparations; oral powders, solutions, suspensions, and syrups; topical 
preparations). 
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Figure 2.5 Poloxamer 188 a=80, b=27. 
 
2.4.5 Akrysol K 140 
Nonproprietary Names Polyoxyl 40 Hydrogenated Castor Oil 
Polyoxyethylene castor oil derivatives are complex mixtures of various hydrophobic and 
hydrophilic components. Members within each range have different degrees of 
ethoxylation (moles)/PEG units as indicated by their numerical suffix 
Functional Category 
Emulsifying agent; solubilizing agent; wetting agent. 
Regulatory Status 
Included in the FDA Inactive Ingredients Database 
 
2.4.6 Labrasol 
Mixtures of monoesters, diesters, and triesters of glycerol and monoesters and diesters of 
polyethylene glycols with mean relative molecular mass between 200 and 400. 
Functional Category 
Dissolution enhancer; emulsifying agent; nonionic surfactant; penetration agent; 
solubilizing agent; sustained-release agent. 
Regulatory status 
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Included in the FDA Inactive Ingredients Database (oral route: capsules, tablets, 
solutions; 
topical route: emulsions, creams, lotions; vaginal route: emulsions, creams) 
 
2.4.7 Capmul MCM C8 
Synonym: 1,2,3- Propanetriol 
Functional Category 
Emollient; emulsifying agent; solubilizing agent; stabilizing agent; sustained-release 
agent; tablet and capsule lubricant. 
Regulatory Status 
GRAS listed. Included in the FDA Inactive Ingredients Database (oral capsules and 
tablets; ophthalmic, otic, rectal, topical, transdermal, and vaginal preparations). 
2.4.8 Capryol 90 
Common name : Propylene glycol monocaprylate 
Physical appearance : Oily liquid 
HLB Value : 6 
Functional category 
CapryolTM 90 is an oily liquid used in oral and topical formulations. 
It is a solubilizer/bioavailability enhancer for oral formulations. 
It can be used in Self Emulsifying Lipidic Formulations (SELF type SMEDDS). 
It is a solubilizer/penetration enhancer for topical formulations. 
It is a co-surfactant for microemulsions in topical formulations.  
Regulatory status  
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Approved by FCC and USFA 
2.4.9 Labrafac PG 
Common name : Propylene glycol dicaprylocaprate 
Physical Form : Oily liquid 
HLB Value : 2 
Functional category 
LabrafacTM PG is a liquid oily vehicle for use in oral and topical formulations: 
For oral formulations, it has solubilizing properties for lipophilic drugs. 
It can be used in Self Emulsifying Lipidic Formulations (SELF type SEDDS/SMEDDS). 
It is an oily phase for microemulsions in topical formulations. 
Regulatory status 
Approved by USFA 
 
2.4.10 Lauroglycol 90 
Common name : Propylene glycol monolaurate 
Physical appearance : Liquid 
HLB Value : 5 
Functional category 
Lauroglycol 90 is a liquid used in oral and topical formulations: 
It is a solubilizer/bioavailability enhancer for oral formulations. 
It can be used as a surfactant in Self Emulsifying Lipidic Formulations (SELF type 
SMEDDS). 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 38
Introduction 2 
 
 
It is a solubilizer/penetration enhancer for topical formulations. 
It is a co-surfactant for microemulsions in topical formulations. 
Regulatory status 
Included in the FDA Inactive Ingredients Database 
2.4.11 Transcutol P 
Common name : Diethylene glycol monoethyl ether 
Physical appearance : Liquid 
Functional category 
Transcutol P is suitable for oral dosage forms. 
It is a high performance solubilizer/solvent for many poorly soluble compounds. 
It is soluble in both water and oil. 
Regulatory status 
Included in the FDA Inactive Ingredients Database 
 
Figure 2.6 Transcutol 
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Review of Work done on dissolution enhancement of Glibenclamide (Glyburide) 
 
Objective Method Conclusion Reference 
To investigate the most effective third 
component which can be used with 
hydroxylpropyl-β-cyclodextrin (HPβCd) to form 
a ternary complex with glyburide in order to 
enhance its dissolution rate. 
Sodium lauryl sulphate, Poloxamer-
188, polyvinylpyrrolidone K-30, 
lactose and l-arginine were used to 
formulate ternary system along with 
HPβCd and glyburide. 
The ternary system formulated 
with glyburide:HPβCd:l-arginine 
in a proportion of 1:1:0.5 has 
shown the fastest dissolution rate 
when compared to other 
solubilizing agents. 
(SK.  Singh, 
Srinivasan, 
Singare, 
Gowthamarajan, 
& Prakash, 
2012) 
To investigate the use of liquisolid technique in 
improving the dissolution of glyburide in a solid 
dosage form. This study was designed to 
evaluate the effects of different formulation 
variables, on drug dissolution rates. 
The liquisolid tablets were formulated 
with Propylene glycol, as liquid 
vehicle. Microcrystalline cellulose was 
used as a carrier material, silica as a 
coating material and croscaremellose 
as a disintegrant 
The liquisolid tablets prepared 
with PVP showed a remarkably 
improved dissolution rate. 
(SK. Singh et 
al., 2012) 
A combination of a non-aqueous freeze drying 
step (bottom-up), followed by wet ball milling 
or high pressure homogenization (top-down) to 
The crystal habit of the model drug 
glibenclamide was modified by freeze 
drying from dimethyl sulfoxide 
Improved drug dissolution was 
seen. 
(Salazar, 
Ghanem, 
Müller, & 
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produce fine drug nanocrystals. (DMSO)/tert-butanol (TBA) solvent 
mixtures using different ratios 
Möschwitzer, 
2012) 
Developed effective microemulsion 
formulations using glyburide (a very poorly-
water-soluble hypoglycaemic agent) as a model 
drug. 
A 13-run mixture design was carried 
out in an experimental region defined 
by constraints on three components: 
aqueous, oil and 
surfactant/cosurfactant. 
The ME formulation optimized 
via the mixture experiment 
approach consisted of 78% 
surfactant/cosurfacant (a mixture 
of Tween 20 and Transcutol 
(Furlanetto, 
Cirri, Piepel, 
Mennini, & 
Mura, 2011) 
To develop a new solid self-micro-emulsifying 
drug delivery system (S-SMEDDS) to improve 
the dissolution properties of poorly water-
soluble drugs, such as glyburide. 
Liquid self-micro-emulsifying drug 
delivery systems (SMEDDS) 
consisted of Labrafac-Hydro(®), 
Tween(®) 20, Transcutol(®), and 
drug. S-SMEDDS were prepared by 
adsorption of SMEDDS onto different 
adsorbents 
The developed tablets showed the 
advantages of SMEDDS, 
allowing a strong improvement of 
drug dissolution, together with 
increased physical and chemical 
stability. 
(Mura, Valleri, 
Cirri, & 
Mennini, 2010) 
To develop and characterize self-
nanoemulsifying drug delivery system 
(SNEDDS) of the poorly water-soluble drug, 
glibenclamide 
Phase diagrams were constructed to 
identify efficient self-emulsification 
region using oils, surfactants, and 
cosurfactants in aqueous environment. 
The results of this study indicate 
that the self-nanoemulsifying 
drug delivery system of GBD, 
owing to nanosize, has potential 
to enhance its absorption and 
(SK. Singh, 
Verma, & 
Razdan, 2010) 
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without interaction or 
incompatibility between the 
ingredients 
The objective of the present investigation was to 
develop and evaluate self-microemulsifying 
drug delivery system (SMEDDS) for improving 
the delivery of a BCS class II antidiabetic agent, 
glyburide (GLY). 
The solubility of GLY in oils, 
cosurfactants, and surfactants was 
evaluated to identify the components 
of the microemulsion. The ternary 
diagram was plotted to identify the 
area of microemulsion existence 
The stability studies indicated 
that GLY undergoes significant 
degradation in the developed 
SMEDDS. This observation was 
totally unexpected and has been 
noticed for the first time. 
(Y. Bachhav & 
Patravale, 2009) 
The ability of hydroxybutenyl-beta-cyclodextrin 
(HBenBCD) to form complexes with glyburide, 
with enhanced solubility and dissolution rate in 
vitro. 
Glyburide and glyburide-HBenBCD 
were evaluated in various test media 
known to simulate human 
gastrointestinal conditions in the 
fasted and fed states, respectively. 
Complexation with HBenBCD 
may be an effective way to 
increase the bioavailability of 
glyburide 
(Klein et al., 
2009) 
To develop glyburide fast-dissolving tablets by 
exploiting the solubilizing effect of different 
cyclodextrins (CDs), alone or in combination 
with hydrophilic polymers 
Drug-CD and drug-CD-polymer 
systems, prepared by different 
techniques, 
drug-PVP-hydroxypropyl-betaCD 
coevaporated tablets gave 100% 
drug dissolution within only 15 
min. 
(Valleri, Mura, 
Maestrelli, 
Cirri, & 
Ballerini, 2004) 
Was to develop Fast Effervescent Tablets of Screened various acid and carbonate FETs of glibenclamide might aid (Jacob, 
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glibenclamide based on highly plastic granules 
that can be compressed at low pressure to form 
fast-melting pharmaceutical tablets 
sources for the effervescent system. 
Citric acid was coated with plastic 
materials such as polyethylene glycol 
(PEG), which provide a physical 
barrier to the reaction 
in dissolution due to increase in 
microenvironmental pH around 
the granules and saliva 
Shirwaikar, & 
Nair, 2009) 
Investigated the effect of the addition to a 
reference tablet formulation of different types 
(anionic and nonionic) and amounts of 
hydrophilic surfactants,  
Suitable formulations containing the 
drug with each surfactant or drug: 
PEG: surfactant ternary were 
prepared. 
The best product was the 
10:80:10 w/w ternary dispersion 
with PEG 6000 and sodium 
laurylsulphate,  
(Cirri, 
Maestrelli, 
Corti, Mura, & 
Valleri, 2007) 
The effect of chitosan and of different 
concentrations of beta- or hydroxypropyl-beta-
cyclodextrins, separately or in various (w/w) 
combinations, on the dissolution characteristics 
of glyburide  
Cyclodextrins and chitosan Synergistic effect in enhancing 
glyburide apparent permeability 
was revealed in permeation 
experiments. 
(Zerrouk et al., 
2006) 
Solid dispersions (SDs) of glibenclamide 
(GBM); and polyglycolized glycerides with the 
aid of silicon dioxide as an adsorbent, were 
prepared by spray drying technique 
SDs and spray dried GBM in 
comparison with pure GBM and 
corresponding physical mixtures 
(PMs) were initially characterized and 
then subjected to ageing study up to 3 
Obtaining stable free flowing SDs 
of poorly water-soluble drugs 
using polyglycolized glycerides 
carriers with the aid of silicon 
dioxide as an adsorbent were 
(Chauhan, 
Shimpi, & 
Paradkar, 2005) 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 43
Literature review 3 
 
months. produced. 
The purpose of this work is to improve the 
dissolution and bioavailability characteristics of 
glibenclamide as compared to Daonil tablets. 
Solid dispersions of glibenclamide in 
Gelucire 44/14 and in polyethylene 
glycol 6000 (PEG 6000) were 
prepared by fusion method 
The ranking in term of dissolution 
rate and extent of absorption 
follows: Formula 2>Formula 1 
>Daonil. 
(Bassam M. 
Tashtoush, 
Zubaida S. Al-
Qashi, & Najib, 
2004) 
Investigated the possibility of developing 
glyburide tablets, allowing fast, reproducible, 
and complete drug dissolution, by using drug 
solid dispersion in polyethylene glycol 
The effects of several variables related 
to both solid dispersion preparation 
and tablet production  on drug 
dissolution behavior were investigated 
dissolution profile from the newly 
developed tablets was clearly 
better than those from various 
commercial tablets at the same 
drug dosage. 
(Valleri et al., 
2004) 
The ability of liquid and semi-solid matrix 
(SSM) filling capsule technology to improve the 
dissolution rate of glibenclamide (GBD) was 
investigated. 
GBD was formulated in different 
concentrations as solutions in 
tetraglycol or tetraglycol/ PEG 6000 
blend and as suspensions in SSM 
composed of Gelucire 44/14 as a base 
Dissolution rate studies revealed 
that the release profiles of GBD 
from capsule formulations 
containing the drug in 
concentrations up to 3.5%  were 
comparable. 
(Galal, El- 
Massik, 
Abdallah, & 
Daabis, 2003) 
The synthesis of hydroxybutenyl 
cyclomaltooligosaccharides (cyclodextrins) and 
he hydroxybutenyl cyclodextrin ethers 
were found to be highly water soluble. 
Significant increases in the 
solubility of the free drugs were 
(Buchanan et 
al., 2002) 
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the ability of these cyclodextrin ethers to form 
guest-host complexes with guest molecules to 
improve dissolution of glyburide 
Complexes of HBen-beta-CD with 
glibenclamide and ibuprofen were 
prepared and isolated. 
observed which did not decrease 
with time. 
Study was to formulate and evaluate 
proliposomes in the form of enteric-coated 
beads using glyburide as a model drug. 
The beads were enteric coated with 
Eudragit L-100 by a fluidized bed 
coating process using triethyl citrate as 
plasticizer 
Enteric-coated beads exhibited 
enhanced dissolution compared 
with pure drug and a marketed 
product 
(R. Kumar, 
Gupta, & 
Betageri, 2001) 
The effect of aging on the physicochemical 
stability of glibenclamide (GB)/beta-
cyclodextrin (CD) systems and tablets made 
with CD-complexed GB was studied. 
The products were unaffected even 
after a storage period of 4 years, 
except that the crystallinity of GB/CD 
physical mixture was decreased with 
aging. 
The dissolution rate of the 
kneaded mixture, inclusion 
complex, and tablets made with 
the inclusion complex were 
unaffected on storage for 4 years. 
(Babu & Pandit, 
1999) 
Investigated the enhancement of the solubility 
of glibenclamide  by cogrinding it with highly 
branched cyclic dextrin (HBCD) using a ball 
mill. 
GCM crystals were coground with 
HBCD for 2 h, the solubility of GCM 
was improved to 12.4 µg/ml 
Results suggested the formation 
of solid dispersion 
between GCM and HBCD 
(Fukami et al., 
2006) 
To allow faster dissolution of drug 
Drug solid dispersion in hydrophillic 
carrier 
Improved drug dissolution was 
observed. 
(Valleri et al., 
2004) 
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Review of Work done on dissolution enhancement of Glimepiride 
Objective Method Purpose Reference 
The feasibility of incorporating a solid 
dispersion of  glimepiride and poly(ester 
amide) was investigated 
Tablet cores were additionally 
coated with hydroxypropyl 
methylcellulose phthalate in order 
to protect the hygroscopic solid  
Glimepiride solubility also deteriorates 
somewhat, most probably due to its 
partial recrystallization 
(Reven, Homar, 
Peternel, Kristl, & 
Zagar, 2011) 
Solid dispersions of glimepiride, and 
poly(ester amide) hyperbranched were 
prepared in order to improve 
glimepiride's poor water solubility 
X-ray powder diffraction results 
show that glimepiride is in 
noncrystalline form, indicating that 
drug molecules are molecularly 
dispersed within the amorphous 
hyperbranched polymers. 
glimepiride's water solubility and its 
dissolution rate are considerably 
improved relative to the pure 
glimepiride drug. 
(Pahovnik et al., 
2011) 
Solid dispersion (SD) and micronized 
techniques, for improving oral absorption 
of poorly soluble glimepiride was 
investigated 
SD was prepared by a solvent-
evaporation process with povidone 
k-30 (PVPk30) while the other was 
prepared via a modified 
micronization technique,  
studies confirmed that both SD and 
micronization techniques were capable 
of improving dissolution and oral 
absorption of glimepiride tablets  
(Ning et al., 2011) 
To study the feasibility of using 
hyperbranched polymers with highly 
In vitro dissolution studies showed 
significantly enhanced aqueous-
Due to complex formation, glimepiride 
is within solid dispersions with HB 
(Reven, 
Grdadolnik, Kristl, 
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branched structure as solubilization 
enhancers for poorly water-soluble drugs 
with glimepiride as model drug 
solubility of glimepiride in the form 
of solid dispersions  
polymers amorphous up to 
concentration of 5% (w/w) 
& Zagar, 2010) 
Drug-free microparticles were prepared 
using a spray congealing process with the 
intention of studying the influence of 
processing parameters 
Microparticles with median sizes 
d(0.5) from 58 to 278 micron were 
produced, with total process yields 
ranging from 81% to 96%. 
All glimepiride-loaded microparticles 
showed enhanced solubility compared to 
pure drug; however, Gelucire 50/13 as a 
carrier represents the most promising 
approach to the dissolution rate 
enhancement of glimepiride.  
(Ilić et al., 2009) 
Developed an easily swallowed film 
formulation that swells and turns into a 
jelly instantaneously upon absorption of a 
small amount of saliva. 
A dissolution study confirmed the 
delayed dissolution of glimepiride 
as a model drug. 
the film formulation passed the 
esophagus and reached the stomach 
quickly. 
(Okabe et al., 
2008) 
A dissolution method for the assessment 
of 4 mg glimepiride tablets was 
developed and validated. 
Optimal dissolution conditions were 
1000 mL of phosphate buffer (pH 
6.8) containing 0.1% (w/v) of SDS 
as the dissolution medium  
A significant influence of polymorphism 
on the dissolution properties of 
glimepiride tablets was observed 
(Bonfilio et al., 
2012) 
Inclusion complexes of glimepiride in -
Cy D, HP--CyD and SBE--CyD with or 
Phase solubility diagrams revealed 
increase in solubility of the drug 
In conclusion, the association of water 
soluble polymers with glimepiride–CyD 
(H.O. Ammar, 
H.A.  Salama, M.  
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without water soluble polymers were 
prepared by the kneading method 
upon cyclodextrin addition. systems leads to great enhancement in 
dissolution rate,  
Ghorab, & A.A. 
Mahmoud, 2006a) 
The effect of complexation of glimepiride 
(HP--CyD and SBE--CyD) in presence of 
different concentrations of water-soluble 
polymers (HPMC, PVP, PEG 4000 and 
PEG 6000) on the dissolution rate of the 
drug has been investigated. 
An optimum increase in the 
dissolution rate of the drug was 
observed at a polymer concentration 
of 5% for PEG 4000 or PEG 6000 
and at 20% concentration of HPMC 
or PVP 
The dissolution rate of the drug from the 
ternary system glimepiride–HP- 
-CyD–5% PEG 4000 was high 
compared to the other systems 
(H.O. Ammar, 
H.A. Salama, M. 
Ghorab, & A.A. 
Mahmoud, 2006b) 
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`Sr. 
No. 
Drug/s 
Route of 
administration 
Purpose 
Method of 
preparation 
Reagents and chemicals Reference 
1 Tamoxifen injection 
Enhance solubility 
and penetration 
microfluidizer Ethanol and Tween 80 
(Tagne, Kakumanu, 
Ortiz, Shea, & 
Nicolosi, 2008) 
2 Probucol i.v. Improve absorption Glass mixing 
Cremophor RH40, 
Maisine 35-1, Lecithin 
(Nielsen, Petersen, & 
Mullertz, 2008) 
3 Carbamazepine parenteral 
For parenteral 
delivery 
Spontaneous 
emulsification 
Soyalecithin, MCTs, 
polyoxyl 35 castor oil 
(Kelmann, Kuminek, 
Teixeira, & Koester, 
2007) 
4 
Cefpodoxime 
proxetil 
oral 
Improve 
bioavailability 
Spontaneous 
emulsification 
Many surfactants 
(A.A. Date & 
Nagarsenker, 2007) 
5 ibuprofen, oral 
Improve 
dissolution rate 
Spontaneous 
emulsification 
Alkyl oleates  IPM 
(L. Wang, Dong, 
Chen, Eastoe, & Li, 
2009) 
6 Ramipril oral 
Improve 
bioavailability 
Spontaneous 
emulsification 
Sefsol 218, Triacetin, 
IPM, Labrafac, 
(Shafiq et al., 2007) 
7 Simvastatin oral 
Improve 
bioavailability 
Spontaneous 
emulsification 
Carbitol, Labrasol,  
Cremophor, Capryol 
(Kang et al., 2004) 
8 Ketoprofen oral Controlled release Spontaneous Capmul and Captex (Pradeep  Patil, Joshi, 
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gel emulsification  & Paradkar, 2004) 
9 Curcumin. oral 
Solubility and 
absorption 
Spontaneous 
emulsification 
Cremorphor, poloxamer 
188 
(J. Cui et al., 2009) 
10 Felodipine oral Extended Release 
Spontaneous 
emulsification 
Migylol, Capmul, 
Cremophor 
(P. R. Patil, Biradar, 
& Paradkar, 2009) 
11 Phenytoin oral 
compare its relative 
bioavailability 
Spontaneous 
emulsification 
Labrafac Labrasol 
Lauroglycol FCC, 
Transcutol 
(Atef & Belmonte, 
2008) 
12 Ramipril, oral 
idea for selection 
of nanoemulsion 
formulations 
Spontaneous 
emulsification 
Sefsol 218, Carbitol, 
Labrafac 
(Shafiq et al., 2007) 
13 Primaquine oral 
Investigate 
antimalarial 
activity 
High speed and 
high pressure 
homogenization 
Poloxamer 188, Egg 
lecithin, Soyabean 
lecithin 
(K. K. Singh & 
Vingkar, (2008) ) 
14 
Camphor, menthol 
and methyl 
salicylate 
topical 
Powerful 
permeation ability 
High speed and 
high pressure 
homogenization 
Tween 80, Poloxamer 
188 etc 
(Mou et al., 2008) 
15 Nabumetone topical 
Improved in vitro 
permeation 
Homogenization 
and sonication 
Alkylglycerols 
(Madhusudhan, 
Rambhau, Apte, & 
Gopinath, 2006) 
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16 Saquinavir Oral and i.v. 
Enhanced oral 
bioavailability and 
brain dispostion 
Spontaneous 
emulsification 
Lipoids and 
deoxycholic acids 
(Vyas et al., 2008) 
17 Artemether oral 
Improve 
antimalarial 
activity 
Spontaneous 
emulsification 
Captex 
(Joshi, Pathak, 
Sharma, & Patravale, 
2008) 
18 Risperidone Intranasal Brain targeting 
Spontaneous 
emulsification 
Capmul MCM, 
Transcutol, Propylene 
glycol, Tween 80 
(M. Kumar et al., 
2008) 
19 Aceclofenac. Transdermal 
Improved 
transdermal 
permeation 
Spontaneous 
emulsification 
Labrafil, Labrasol, 
Labrafac 
(Shakeel et al., 2007) 
20 
Atenolol, 
Metoprolol tartrate, 
Danazol 
oral 
Enhance intestinal 
absorption 
Spontaneous 
emulsification 
Pluronics, Transcutol, 
Lauroglycol 
(Brusewitz, 
Schendler, Funke, 
Wagner, & Lipp, 
2007) 
21 flutamide oral 
Improved 
dissolution 
High pressure 
homogenization 
Alkyl glycerols 
(Madhusudhan, 
Rambhau, Apte, & 
Gopinath, 2007) 
22 Loratadine oral To evaluate porous Spontaneous Captex, Capmul (Pradeep Patil & 
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beads as carriers emulsification Paradkar, 2006) 
23 
all-trans-retinol 
acetate 
oral 
Enhanced 
dissolution  
Spontaneous 
emulsification 
Soyabean, Cremophor, 
Capmul MCM 
(Ehab I.  Taha et al., 
2004) 
24 Pueraria lobata oral 
in vitro dissolution 
and oral absorption 
Spontaneous 
emulsification 
Transcutol 
(S. Cui, Zhao, Chen, 
& He, 2005) 
25 Β Lactamase oral 
Oral absorption 
study 
Spontaneous 
emulsification 
Transcutol, 
Laurylglycol, 
Cremophor 
(Sripriya Venkata 
Ramana Rao et al., 
2008) 
26 
Biphenyl dimethyl 
dicarboxylate 
oral 
Enhanced 
bioavailability  
Spontaneous 
emulsification 
Transcutol, 
Laurylglycol, 
Cremophor 
(El-Laithy, 2008) 
27 
Labelled Β 
Lactamase 
oral 
Improve oral 
bioavailability 
Spontaneous 
emulsification 
Labrafil, Labrasol, 
Labrafac 
(Sripriya Venkata 
Ramana  Rao & Shao, 
2008) 
28 Ezetimibe oral 
Improve oral 
bioavailability 
Spontaneous 
emulsification 
More excipients 
(Dixit & 
Nagarsenker, 2008) 
29 Glibenclamide oral 
Improve delivery 
of glibenclamide 
Spontaneous 
emulsification 
Solutol, Labrafil, 
Pluorol oleque, 
Labrasol, Transcutol 
Capmul MCM 
(Y. G. Bachhav & 
Patravale, June 2009) 
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Review of work done on preparation on nanosuspensions by precipitation 
Sr. 
No. 
Drug/s 
Route Of 
Administration 
Purpose 
Method of 
Preparation 
Reagents and 
Chemicals 
Reference 
1 AZ68 i.v. and oral 
Comparison of solution 
and 
amorphous/crystalline 
nanosuspensioon 
precipitatin technique 
and milling in 
Planetary micro mill 
SDS ,PVP K 30, 
DOSS, Miglyol 
(Sigfridsson , 
Forsse´n, 
Holla¨nder, 
Skantze, & 
Verdier, 
2007) 
2 Ibuprofen 
Opthalmic 
delivery 
Improve the availability 
Quasi emulsion 
diffusion technique 
Eudragit RS100, 
Tween 80 
(Pignatello et 
al., 2002) 
3 Albendazole Oral 
To compare the various 
method of preparing 
nanosuspensions with 
more importance of high 
pressure homogenization 
High Pressure 
Homogenization, 
Nanoprecipitation, 
Sonication and 
Milling 
Tween 80, 
Cremophor RH40, 
SDS, Carbopol, 
HPMC, 
Poloxamer 
(M. P. 
Kumar, Rao, 
& Apte, 
2008) 
4 Mitotane - 
feasibility of the various 
water miscible solvents 
to prepare 
nanosuspensions 
By solvent quenching 
technique 
Benzyl Alcohol, 
Butyl Lactate, 
Triacetin 
(Michele.  
Trotta, 
Gallarate, 
Pattarino, & 
Morel, 2001) 
5 Carbamazepine Oral 
To design a process to 
enhance the dissolution 
of poorly water soluble 
drugs 
Evaporative 
precipitation  
technique 
Pluronic F127, 
SDS, PVP K15, 
DCM, NaDC 
(Sarkari et 
al., 2002) 
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6 Cefuroxime Axetil Oral 
To investigate the 
feasibility of production 
of nanoparticles by 
controlled 
nanoprecipitation 
without surfactants. 
Nanoprecipitation 
technique involving 
quick transfer of 
organic solvent into 
aqueous solvent 
- 
(J.-Y. Zhang 
et al., 2006) 
7 
Progesterone, 
β 
MethasoneValerat
e 17, 
Carbamazepine 
and oxcarbazepine 
 
Development of a newer 
technique for the 
production of nano and 
micro particles 
Dissolution of drug in 
organic phase and 
mixing of the solvent 
in aqueous phase 
Gelatine, HPMC, 
Lutrol F 68, 
Lipoid S75 
(Douroumis 
& Fahr, 
2006) 
8 Griseofulvin Oral 
To prepare griseofulvin 
nanocapsules and 
nanospheres to enhance 
dissolution and solubility 
Polycaprolactone is 
dissolved in acetone 
to prepare 
nanospheres and to 
prepare nanocapsules 
an oil is added to the 
organic phase 
Tween 80, span 
80, Benzyl 
benzoate, Acetone 
(Zili et al., 
2005) 
9 Griseofulvin Oral 
To prepare 
microemulsions and use 
them as a template for 
preparation of 
nanosuspensions 
Microemulsion were 
formed and then water 
was added to prepare 
drug nanosuspensions 
General excipients 
(Michele. 
Trotta, 
Gallarate, 
Carlotti, & 
Morel, 2003) 
10 Cephradine Injection 
To investigate the 
feasibility of method to 
improve dissolution of 
Reactive and anti 
solvent precipitation 
- 
(Zhong, 
Shen, Yang, 
& Chen, 
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cephadrine for injection 2005) 
11 Cyclosporine A i.v. / oral 
To investigate the 
feasibility of method 
Evaporative 
precipitation into 
aqueous solution 
Brij 97, Myrj 52, 
Pluronic F127, 
PVP, Tween 80, 
PEG 
(X. Chen et 
al., 2002) 
12 Albendazole Oral 
Improvement of 
Bioavailability 
High Pressure 
Homogenisation 
Lutrol F 68, 
HPMC, Tween 80 
(M. P. Kumar 
et al., 2008) 
13 Cyclosporin 
Pulmonary 
Delivery 
To investigate different 
mechanisms employed in 
preparation and 
subsequent performance 
of dosage form 
Antisolvent 
precipitation Vacuum 
distillation was used 
to remove methanol, 
Itracanazole, 
Tween 80 
Lyophillization of 
nanoparticles for 
subsequent use 
(Tam, 
Mcconville, 
Williams III, 
& Johnston, 
2008) 
14 
All Trans Retinoic 
Acid 
Oral 
To increase saturation 
solubility and investigate 
the feasibility of method 
Modified precipitation 
method using HPLC 
pump 
sonicator was used 
for precipitation in 
aqueous solution, 
acetone was 
removed using 
water circulation 
vacuum pump 
(Zhang, Xia, 
& Gu, 2006) 
15 β-Cypermethrin pesticide 
To achieve high drug 
loading 
Microemulsion 
emulsion dilution 
technique 
Microemulsion is 
diluted with water 
and then 
centrifuged 
(Zeng, Li, 
Zhang, & 
Dong, 2008) 
16 
Iuprofen 
(Model Drug) 
Oral 
Comparison of method 
of preparation, 
micorfluidization and 
Stability is more at 
4
O
C than at 25
O
C 
Normal 
surfactants 
(Galindo-
Rodr´ıguez et 
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precipitation under 
sonication 
al., 2005) 
17 Cefuroxime Axetil Oral 
For enhancement of 
bioavailability 
Probe sonicator  for 
ultrasonication and 
spray drying 
No 
(Dhumal, 
Biradar, 
Yamamura, 
Paradkar, & 
York, 2008) 
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Review of literature of work done on nanosuspensions by media milling.
Sr. 
No. 
Drug/s 
Route Of 
Administration 
Purpose Method of Preparation 
Reagents and 
Chemicals 
Reference 
1 Naproxen Oral 
Decrease gastric toxicity 
and enhance absorption 
Zirconium beads in 
Roller mill 
Pluronic F68 
(G. G. Liversidge & 
Conzentino, 1995) 
2 
Fluticasone and 
Budesonide 
Intratracheal 
Investigate Pulmonary 
administration 
milling Tween 80 
(Yang, Young, 
Chiang, Thurston, & 
Pretzer, 2008) 
3 
Beclomethasone 
Dipropionate 
Pulmonary 
Nebulization of 
Nanocrystals 
Ball mill 
PVA (30,000-
70,000) 
(Wiedmann, 
DeCastro, & Wood, 
1997) 
4. hydrocortisone Oral Improve dissolution 
Media milling and 
nanoprecipitation 
HPMC 
PVP K 30 
(Ali, York, Ali, & 
Blagden, 2011) 
5. 
Phenytoin and 
nifedipine 
 
to  support the discovery 
and preclinical studies 
using animals 
Wet milling using 
zirconia beads 
PVA, L-HPC, 
PVP grades 
(Niwa et al., 2011) 
6. 
Itraconazole and 
indomethacin 
oral Improved dissolution 
Rapid wet milling 
technique 
Pluronic F68 
Pluronic F127 
(Liu et al., 2011) 
7. 
Reviewed very recently the various advances, application in wet milling technology with future 
perspectives 
(Merisko-Liversidge 
& Liversidge, 2011) 
8. 
Reviewed the most important factors affecting nanocrystal formulation and efficacy of stabilizers. In order 
to widen understanding of the milling process, the most important variables related to milling techniques 
and particle fracturing processes during the milling were presented. 
(Peltonen & 
Hirvonen, 2010) 
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Yadunathji 
The following resources were used in the present study 
Table 4. 1 List of materials used during the study 
List of Materials Used Suppliers 
Glibenclamide (Glyburide) 
Glimepiride 
Gift Sample from Cadila Pharma Pvt. 
Ltd., Ahmedabad 
Capmul MCM C8 
Gift Sample from Abitec Corporation 
USA 
Transcutol P, Labrafac PG, Pluoreol 
Oleique, Capryol 90 
Gift Sample from Gattefosse India Pvt. 
Ltd., Mumbai. 
PVP S 630 D 
Gift Sample from ISP Chemicals, 
Singapore 
Zirconia beads (0.1 mm, 1.0 mm,) 
Glass beads (1.0 mm) 
Purchased from Unigenetics Pvt. Ltd., 
Delhi 
Acrysol K 140, Acrysol K 150, 
Acrysol K 160 
Gift sample from Corel Pharmachem 
India, Ahmedabad. 
Poloxamer 188 
Gift Sample from Cadila Pharma Pvt. 
Ltd., Ahmedabad 
Tween
®
 80, Hydrochloric Acid, Methanol, 
Sodium Hydroxide Pellets (A.R. Grade), 
Potassium Hydrogen Phosphate (A.R. 
Grade), Sodium Lauryl Sulphate, Acetone, 
Dichloromethane, Ethyl Oleate, Hydroxy 
Propyl Methyl Cellulose, Hydroxy ethyl 
cellulose 
Purchased from S.D.Fine-Chem Ltd., 
Mumbai. 
Water 
Double Distilled Water prepared in the 
laboratory 
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Table 4. 2 List of equipments used during the study 
List of Equipments Manufacturing Company 
Mechanical Stirrer Remi Equipments Pvt. Ltd, India 
Magnetic stirrer Remi Equipment Pvt. Ltd, India 
Hot air oven Sun Instrument Pvt. Ltd, India 
pH meter EI products, Model 111, India 
Digital weighing balance Shimadzu, Japan 
Ultrasound Sonicator Trans-o-Sonic, India 
Dissolution rate test apparatus 
Electrolab Dissolution Tester TDT-06P, 
USP 
UV/VIS Double beam Spectrophotometer 
Shimadzu 1800  UV/VIS       
Spectrophotometer, Japan 
Microscope Usico, India 
FTIR Nicolet iS10 FT-IR Spectrometer, Japan 
X-Ray diffractometer MiniFlex, Rikagu Inc., USA 
Particle size analyzer Zetatrac, Microtrac, USA 
 
List of software used during the study: The following software were used during 
the study 
Microsoft Office 2007 
Minitab 16 (Minitab Inc., USA) 
Statistica 8.0 (StatSoft Inc, USA) 
Sigma Plot 11.0 (Sigma Plot Inc, USA) 
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4.3 Preparation of Reagents and Solutions (As per Indian Pharmacopeia) 
Preparation of 0.1 M HCl 
M HCl was prepared by diluting 8.5 ml of concentrated hydrochloric acid to 1000 ml 
with distilled water. 
 
Preparation of 0.2 M pH 7.5 phosphate buffer 
Place 50 ml of 0.2 M potassium dihydrogen phosphate in a 200 ml volumetric flask, 
add 39.1 ml of 0.2 m sodium hydroxide and then add distilled water to make volume 
to 200 ml. 
 
Preparation of 0.2 M pH 7.8 phosphate buffer 
Place 50 ml of 0.2 M potassium dihydrogen phosphate in a 200 ml volumetric flask, 
add 44.5 ml of 0.2 m sodium hydroxide and then add distilled water to make volume 
to 200 ml. 
 
Preparation of 0.2 M potassium dihydrogen phosphate solution. 
Dissolve 27.218 g of potassium dihydrogen phosphate in distilled water and dilute 
with distilled water to 1000 ml. 
 
Preparation of 0.2 M sodium hydroxide solution. 
Dissolve 8.0 g of sodium hydroxide in distilled water and dilute with distilled water to 
1000 ml. 
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4.4 Identification of Drugs 
1. Glibenclamide 
The melting point of Glibenclamide (GLB) was determined by employing Thiel’s 
tube method using liquid paraffin bath. The determination was done in triplicate and 
the average value was found to be 169 ± 2
o
C, which was in close agreement with the 
previously published literature data. 
 
Identification of Drug by Ultra Violet Spectrophotometry: 
0.001% w/v solution of GLB was prepared in 0.2 M pH 7.5 phosphate buffer and 
scanned using UV/VIS Spectrophotometer in the UV range. The λmax was found to be 
229.8 nm which was comparable previously available literature. 
 
Figure 4. 1 UV Visible spectra of glibenclamide in 0.2 M pH 7.5 phosphate buffer  
 
Identification of GLB by Fourier Transform Infrared Spectra: 
FTIR spectrum of pure drug was taken, the scanning was performed at moderate 
speed i.e. between 4000-650 cm
-1
 using Nicolet iS10 FT-IR Spectrometer. The 
obtained spectrum was compared with the reference spectra. 
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Figure 4. 2 FT-IR spectra of pure glibenclamide 
Standard Curve: Standard curve of GLB was taken in pH 7.5 phosphate buffer. 
Standard curve in pH 7.5 phosphate buffer 
Preparation of Stock Solution: 10 mg of GLB was dissolved in 20 ml of 0.1 M NaOH  
in 50 ml volumetric flask, the volume was made upto the mark with 0.1 M NaOH and 
the flask was sonicated for 30 minutes to dissolve GLB completely. From this 10 ml 
of solution was taken and diluted up to the mark in a 50 ml volumetric flask with pH 
7.5 phosphate buffer. 
 
This stock solution was scanned spectrophotometrically between 200-400nm in 
UV/VIS Double Spectrophotometer to determine λmax. The λmax was found to be 229.8 
nm which was in agreement with other previously reported literature. 
 
Preparation of Test solutions: From this stock solution appropriate volume of solution 
was pipetted out and transferred to 10 ml volumetric flasks and the volume was made 
upto the mark using pH 7.5 phosphate buffer to give final strength of 2, 4, 6, ....18 
μg/ml. Standard curve was taken by scanning test solutions against  pH 7.5 phosphate 
buffer as blank. 
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Figure 4. 3 Calibration curve of glibenclamide in 0.2 M pH 7.5 buffer 
 
Table 4. 3 Regression parameters 
Multiple R 0.9998 
R square 0.9997 
Adjusted R square 0.9997 
Standard error 0.0036 
Equation Absorbance = 0.00174 + 0.0509 Concentration 
 
Conclusion 
The drug obtained was glibenclamide and the spectrophotometric determination 
linearity range observed was from 2 µg/ml -18 µg/ml. 
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2. Glimepiride 
The melting point of glimepiride (GMP) was determined by employing Thiel’s tube 
method using liquid paraffin bath. The determination was done in triplicate and the 
average value was found to be 208 ± 2
o
C, which was in close agreement with the 
previously published literature. 
Identification of Drug by Ultra Violet Spectrophotometry: 
0.001% w/v solution of GMP was prepared in 0.2 M pH 7.8 phosphate buffer and 
scanned using UV/VIS Spectrophotometer in the UV range. The λmax was found to be 
229.0  nm which was comparable with the previously published literature. 
 
Figure 4. 4 UV Visible spectra of glimepiride in 0.2 M pH 7.8 phosphate buffer  
 
Identification of GMP by Fourier Transform Infrared Spectra: 
FTIR spectrum of pure drug, the scanning was performed at moderate speed i.e. 
between 4000-650 cm
-1
 using Nicolet iS10 FT-IR Spectrometer. The obtained 
spectrum was compared with the reference spectra. 
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Figure 4. 5 FT-IR spectra of pure glimepiride 
 
Standard Curve: Standard curve of GMP was taken in pH 7.8 phosphate buffer. 
Standard curve in pH 7.8 phosphate buffer 
Preparation of Stock Solution: 10 mg of GMP was dissolved in 20 ml of 0.1 M NaOH  
in 50 ml volumetric flask, the volume was made upto the mark with 0.1 M NaOH and 
the flask was sonicated for 30 minutes to dissolve GMP completely. From this 10 ml 
of solution was taken and diluted upto the mark in a 50 ml volumetric flask with pH 
7.8 phosphate buffer. 
 
This stock solution was scanned spectrophotometrically between 200-400nm in 
UV/VIS Double Spectrophotometer to determine λmax. The λmax was found to be 229.0 
nm which was in agreement with other previously reported literature.  
 
Preparation of Test solutions: From this stock solution appropriate volume of solution 
was pipetted out and transferred to 10 ml volumetric flasks and the volume was made 
upto the mark using pH 7.8 phosphate buffer to give final strength of 2, 4, 6, ....18 
μg/ml. Standard curve was taken by scanning test solutions against  pH 7.8 phosphate 
buffer as blank. 
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Figure 4. 6 Calibration curve of glimepiride in 0.2 M pH 7.8 buffer 
 
Table 4. 4 Regression parameters 
Multiple R 0.9996 
R square 0.9992 
Adjusted R square 0.9990 
Standard error 0.0080 
Equation Absorbance = - 0.00443 + 0.0499 Concentration 
 
Conclusion 
The drug obtained was glimepiride and the linearity range for spectrophotometric 
determination of drug was observed from 2 µg/ml -18 µg/ml. 
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SNEDDS of GMP 5 
 
Abstract 
The objective of the present investigation was to develop and characterize the self 
nanoemulsifying drug delivery system (SNEDDS) of glimepiride (GMP) a poorly 
soluble drug. Solubility of GMP in various vehicles was determined and ternary phase 
diagrams were constructed using a suitable oil, surfactant and cosurfactant system to 
find out the efficient self emulsification system. A three factor three level Box 
Behnken statistical design was employed to explore the main and interaction effect of 
independent variables namely X1 (amount of Capmul MCM), X2 (amount of Acrysol 
K 140), and X3 (amount of Transcutol P). % Transmittance value (Y1), droplet 
diameter (Y2) and % drug released at 5 minutes (Y3) were the dependent variables. 
Formulation optimization was carried out to optimize the droplet diameter and % drug 
dissolved at 5 minutes. The batch prepared according to the optimized formulation 
showed a close agreement between observed and predicted values. Box Behnken 
statistical design allowed us to understand the effect of formulation variables on the 
rapid dissolution of drug from SNEDDS, and optimize the formulation to obtain a 
rapid drug dissolution at 5 min. 
  
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 67
SNEDDS of GMP 5 
 
5.1. Introduction 
Glimepiride (GMP) [1- (p- (2- (3-ethyle-4-methyl-2-oxo-3-pyrroline-1-carboxamido) 
ethyl) phenyl) sulfonyl)-3-(trans-4-methylcyclohexyl)] figure 5.1, is a potent 
sulfonylurea with established potential benefits such as lower dose, rapid onset, lower 
insulin levels and less-pronounced glucagonotropic effects, insulin-sensitizing and 
insulin-mimetic affects. GMP lowers blood glucose level in patients with Type 2 
diabetes by directly stimulating the acute release of insulin from functioning beta cells 
of pancreatic islet tissue by binding to the SUR1 subunits and block the ATP-sensitive 
K+ channel (RoIkamp, Wernicke-Panten et al. 1996), however GMP is a  poorly 
soluble drug (< 0.004 mg/mL in acidic and neutral media) with relatively high 
permeability through CaCo-2 cell monolayer's (Iwata, Fukami et al. 2009), which 
warrant it to be classified under  BCS Class II classification. It is effectively absorbed 
from the gastrointestinal tract, however, presence of food, certain dietary supplements 
and hyperglycemia can interfere with its dissolution and in turn its absorption 
(Ramon, Raptis et al. 2000), and hence in view of the time required to reach an 
optimal concentration in plasma, GMP may be more effective if given 30 minutes 
before meal (Hardman and Limbird 2001). Conversely, this might reduce patient 
compliance since if after taking the drug the patient is not able to have the meal it 
would result in severe hypoglycemia and if taken with meal, food sequentially would 
interfere with its absorption. Hence, improving the dissolution characteristics of GMP 
might allow concomitant dosing of the drug with food. Various researchers have tried 
to improve the dissolution characteristics of GMP by various traditional techniques 
such as addition of surfactants (Seedher and Kanojia 2008), cosolvency (Seedher and 
Kanojia 2009), solid dispersions and micronization (Ning, Sun et al. 2011), 
cyclodextrin complexation (Ammar, Salama et al. 2006), etc which could improve its 
clinical efficacy.  
 
Figure 5. 1 Glimepiride 
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Recently self nanoemulsifying drug delivery systems (SNEDDS) have been 
formulated to offer improved dissolution which could provide a better control over the 
bioavailability of drug. SNEDDS are isotropic mixtures of oil, surfactants and 
cosurfactants that form fine oil-in-water nanoemulsions upon mild agitation, followed 
by addition into aqueous media, such as gastro intestinal fluids (Taha, Al-Suwayeh et 
al. 2009). Nanoemulsions (NE) consist of very small oil droplets in water, exhibiting 
sizes lower than 300 nm. Like conventional emulsions (with sizes > μm), NE are, 
from a thermodynamic point of view, in a non-equilibrium state. However, the 
kinetics of destabilization of NE is so slow that they are considered kinetically stable 
formulations that are easier to manufacture, and may offer an improvement in 
dissolution rates and extents of absorption, resulting in more reproducible blood–time 
profiles due to the nanometer sized droplets present in turn which might reduce the 
fed and fasted variation in the in vivo performance of the drug (Anton and Vandamme 
2010). Surprisingly no such system has been reported to improve the dissolution 
characteristics of GMP which could improve its therapeutic efficacy, lower the dose 
and allow concomitant dosing with food.  
In light of all this, the present investigation was carried to develop, characterize and 
optimize SNEDDS of GMP, to improve the dissolution characteristics of GMP. 
Preliminarily the ternary phase diagrams were constructed and box behnken design 
(BBD) was adopted and formulation components were optimized to improve the 
release of GMP from SNEDDS. 
5.2. Materials and Methods 
5.2.1 Materials 
Glimepiride (GMP) BP was provided as a gift sample by Cadila Pharmaceuticals, 
Ahmedabad; Tween 80 (Polyoxyethylene 20 sorbitan monooleate HLB value 15), 
Tween 60 (Polyoxyethylene 20 sorbitan monostearate HLB value 14.9), Ethyl oleate, 
polypropylene glycol (PPG, polyethylene glycol 400 (PEG 400) were purchased from 
S.D.Fine chemicals limited. Capryol 90 (Propylene glycol monocaprylate, HLB value 
6), Labrasol (Caprylocaproyl macrogolglycerides, HLB value 14), Labrafac PG 
(Propylene glycol dicaprylocaprate, HLB value 2), Lauroglycol 90 (Propylene glycol 
monolaurate, HLB value 5) and Transcutol P (TP) (Diethylene glycol monoethyl 
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ether) were provided by Gattefosse, Mumbai, India as gift samples. Capmul MCM 
(CMCM) (Glyceryl mono/dicaprylate) was provided as gift sample from Abitec 
Corporation, USA. Acrysol K 140 (AK 140) (PEG 40 hydrogenated castor oil, HLB 
value 16), was provided as gift sample by Corel Pharmachem Ltd., Ahmedabad, India 
and was used after gentle heating at 40
o
C - 50
o
C for two minutes. Size 0 HPMC 
empty capsule shells were received as gift sample from Amneal Pharmaceuticals 
Limited, Ahmedabad, India. Double distilled water was used throughout the study. 
All the reagents and chemicals used were purchased from S.D.fine chemicals Pvt. Ltd, 
Ahmedabad, India. 
5.2.2 Determination of solubility of GMP 
Solubility of GMP was investigated in various buffers, oils and surfactant solutions 
(10 % w/w) using shake flask method. Briefly an excess amount of GMP was added 
to 5 gm of the vehicle. The flask were then sealed with Parafilm, and vortexed (Genei, 
Bangalore) for 10 minutes, in order to facilitate the mixing of the drug with the 
vehicle. Mixtures were then shaken for 3 days in rotary shaker (Remi Instruments, 
India), maintained at 25
o
C and then centrifuged at 4800 rpm (Remi instruments, 
India) for 20 minutes. The supernatant was then filtered using whatman filter paper 
(0.22 µ), and diluted suitably with double distilled methanol and the GMP dissolved 
in various vehicles was measured spectrophotometrically (UV spectrophotometer, 
Shimadzu 1700) at 228 nm (Grbic, Parojcic et al. 2010). 
5.2.3 Screening of surfactants for emulsifying ability 
The emulsification ability of various surfactants was screened to find out the most 
suitable surfactant system for the selected oily phase. Briefly, 300 mg of selected 
surfactant was added to 300 mg of selected oil phase. The mixture was then vortexed 
for 60 s to facilitate the mixing of oil and surfactant. 100 mg of this isotropic system 
was weighed accurately and diluted to 25 ml of distilled water to yield a fine 
emulsion. The ease of emulsification was monitored by noting the number of 
volumetric flask inversions required to give uniform emulsion (Date and Nagarsenker 
2007). The formed emulsions were then evaluated for their transmittance at 638.2 nm 
by UV spectrophotometer, using double distilled water as blank. 
5.2.4 Screening of cosurfactants 
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The cosurfactants have ability to improve the nanoemulsification efficiency. The 
relative effectiveness of cosurfactants was evaluated by adding 200 mg of surfactant 
with 100 mg of cosurfactant, to this 300 mg of Capmul MCM C8 (CMCM) was added 
and vortexed to homogenize the mixture. The isotropic system was weighed 
accurately and diluted with double distilled water to yield a fine emulsion. The ease of 
emulsification was monitored by noting the number of volumetric flask inversions 
required to give uniform emulsion. The formed emulsions were then evaluated for 
their transmittance at 638.2 nm by UV spectrophotometer, using double distilled 
water as blank. 
5.2.5 Construction of ternary phase diagrams 
The first step towards the formulation development was to identify the self 
nanoemulsifying region. To identify the self nanoemulsifying region, ternary 
diagrams of oil, surfactant and cosurfactant were prepared, each representing the apex 
of the triangle (Brusewitz, Schendler et al. 2007). Ternary mixtures with varying 
composition of oil, surfactant and cosurfactant were prepared. The oil composition 
was varied from 25 % w/w to 70 %  w/w, surfactant concentration was varied from 25 
%  w/w to 75 % w/w and the cosurfactant concentration was varied from 0 % w/w  to 
30 %w/w. For any mixture the total of oil, surfactant and cosurfactant was always 100 
%. Briefly the oil, surfactant and cosurfactant were mixed and vortexed for 60 
seconds to facilitate homogenization, and the efficacy of nanoemulsion formation was 
assessed by diluting 100 mg of the mixture up to 25 ml of double distilled water and 
followed by gentle agitation manually. The formulations were assessed for ease of 
emulsification and visual appearance (Date and Nagarsenker 2007). Only clear or 
slight bluish dispersions of droplet size less than 200 nm were considered in the 
nanoemulsion region of the diagram. 
5.3. Box Behnken Experimental Design 
Box Behnken Experimental Design (BBD) was used to optimize and evaluate the 
main effects, interaction effects and quadratic effects of the formulation ingredients of 
GMP loaded SNEDDS. Fifteen experiments were generated by Minitab 16.0 (Minitab 
Inc., U.S.A) for the response surface methodology based on the BBD at three factors 
and three level designs. This design is suitable for exploring quadratic response 
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surfaces and constructing second order polynomial models. The design consists of 
replicated center points and the set of points lying at the midpoint of each edge of the 
multidimensional cube. Three independent variables were selected based on the 
preliminary screening: the oil phase CMCM (X1), the surfactant AK140 (X2) and 
cosurfactant TP (X3). The dependent parameters consisted of % transmittance value 
(Y1), droplet diameter (Y2) and % drug released at 5 minutes (Y3). 
5.4. Preparation of GMP loaded SNEDDS 
The GMP loaded SNEDDS were prepared by mixing oily phase CMCM, surfactant 
AK140 and cosurfactant TP and warming it at 40
0
C, then GMP was added to the 
mixture and vortexed to facilitate the uniform dispersion of GMP. The mixture was 
then allowed to equilibrate at room temperature. Fifteen such experiments were 
carried out according to the experimental design with varying concentration of oil, 
surfactant and cosurfactant with the final GMP loading equivalent 10 mg/gm. The 
prepared GMP loaded SNEDDS were filled into size 0 HPMC capsule shells. 
5.5. Optimization of formulation components  
The formulation components were optimized statistically by Minitab 16 subsequent to 
generating the polynomial equations concerning the dependent and independent 
variables, optimization of Y2 (droplet diameter) and Y3 (% drug released at 5 
minutes) was performed using a desirability function to obtain the levels of X1, X2, 
and X3, which maximized Y3 and minimized Y2. 
5.6. Characterization of GMP loaded SNEDDS 
5.6.1 Droplet diameter and zeta potential measurement 
Droplet diameter and size distribution and zeta potential of SNEDDS were 
determined using Zetatrac (Microtrac Inc., USA). Zetatrac utilizes a high frequency 
AC electric field to oscillate the charged particles. The Brownian motion power 
spectrum is analyzed with modulated power spectrum (MPS) technique, a component 
of power spectrum resulting from oscillating particles. 100 mg of sample was diluted 
to 25 ml of purified water. Diluted samples were directly placed into cuvette and 
measure droplet size and zeta potential. (Dabhi, Limbani et al. 2011). 
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5.6.2 In vitro release studies 
400 mg of formulation containing 4 mg of GMP were filled in size 0 HPMC capsules. 
The release of GMP from the capsules filled with SNEDDS formulation was carried 
out in USP dissolution test apparatus at a rotating speed of 75 rpm in 100 ml pH 7.8 
phosphate buffer for a period of 30 minutes (USFDA and Guidelines). Aliquots of 5 
ml each were withdrawn at selected time interval and were filtered through whatman 
filter paper (0.22µ) and replaced with an equivalent amount of fresh dissolution 
medium. The concentration of GMP was measured spectrophotometrically at 228 nm 
using the regression equation of standard curve developed in the same range in the 
linearity range of 2-18 µg/ml.  
5.6.3 Determination of the emulsification time 
In order to determine the emulsification time (the time needed to reach the emulsified 
and homogeneous mixture, upon dilution) 100 mg of each formulation was added to 
25mL of pH 7.8 buffer at 37
◦
C with gentle agitation using magnetic stirrer. The 
formulations were assessed visually according to the rate of emulsification and the 
final appearance of the emulsion. 
5.6.5 Statistical evaluation 
The experimental data obtained were validated by ANOVA combined with the F-test. 
The determination coefficient (R
2
, agreement between the experimental results and 
predicted values obtained from the model) and the model F-value (Fisher variation 
ratio, the ratio of mean square for regression to mean square for residual) were 
applied for statistical evaluation. 
5.7 In vivo studies of optimized GMP loaded SNEDDS 
Approval to carry out in vivo study was obtained from Department of Pharmaceutical 
Sciences, Saurashtra University, Institutional Animal Ethics Committee, CPCSEA 
Reg. No. 1155/ac/07/CPCSEA and their guidelines were followed for the studies 
Male wistar rats weighing (~250 gm) were kept on standard diet and fasted over 
night. Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and nicotinamide 
was dissolved in normal physiological saline. Non-insulin-dependent diabetes 
mellitus was induced in overnight fasted rats by a single intraperitoneal injection of 
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STZ (45 mg/kg b.w.). 15 min later, the rats were given the intraperitoneal 
administration of nicotinamide (110 mg/kg b.w.). Hyperglycemia was confirmed by 
the elevated glucose levels in plasma, determined at 72 h. The animals with blood 
glucose concentration more than 250 mg/dL were considered to be diabetes and used 
for the experiment (Prabu, Kumarappan et al. 2012). 
The rats were divided into three groups after the induction of STZ-nicotinamide 
diabetes. Animals in the control group received 0.5% carboxy-methyl cellulose 
(CMC) only. The test groups of animals were treated with the test samples suspended 
in the same vehicle in a parallel group design. Intragastric tubing was used to 
administer a single dose of 600µg/kg of the free drug or the equivalent amount of 
GMP loaded SNEDDS. Blood samples were collected at 1,2,3...8 and 24 h after the 
oral administration of test samples. Blood glucose level (BGL) was measured at 
different time intervals, up to 24 h the hypoglycemic response was evaluated as 
percentage decrease in blood glucose level: 
                 
                   
          
      
The pharmacodynamic parameter of the area under percentage decrease in BGL 
versus time curve (AUC0–8h) was calculated adopting the trapezoidal rule. Statistical 
analysis of the results was performed using one-way analysis of variance (ANOVA). 
5.8 Results and Discussions: 
5.8.1 Solubility studies 
The solubility studies of GMP in various oils, surfactants and cosurfactants were 
carried out to identify the suitable oil and surfactant-cosurfactant system to develop an 
appropriate delivery system which enables to dissolve the total dose of the drug. 
Various oils with different degrees of saturation were used and as shown in figure 5.2 
the solubility in oils did not showed any specific pattern and it was seen that amongst 
the various oils assorted, GMP showed highest solubility in CMCM, which was then 
selected as the oily phase, followed by Capryol 90 and Lauroglycol 90. The selection 
of surfactant and cosurfactant was subsequently done based on their ability to 
emulsify the oil. 
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Figure 5. 2 Solubility of GMP is various oils (the data are expressed as average ± 
standard deviation, n =6) 
5.8.2 Screening of surfactants for emulsifying ability 
Non-ionic surfactants are often considered for pharmaceutical applications and self 
nanoemulsifying formulation since these are less toxic and less affected by pH and 
ionic strength changes . Thus, for present study, AK 140, Tween 80, Labrasol, were 
used as surfactants having a higher HLB value. The surfactants were evaluated and 
compared for their emulsification ability using CMCM and Capryol 90 as oily phase, 
since a well formulated self emulsifying drug delivery system should emulsify within 
very less time. The transmittance values for different surfactants are shown in figure 
5.3. The results clearly indicated that AK140 showed the highest emulsification 
efficiency, requiring only single flask inversions for homogenous emulsion formation 
with 99.7 % transmittance suggesting the formation of a very fine emulsion. The 
emulsification efficiency of AK140 was followed by Tween 80, where as Labrasol, 
was poor emulsifier for GMP. The surfactants showed a wide variation in their 
emulsification ability even though they had similar HLB values which could be 
ascribed to their difference in chain length and structure (Date and Nagarsenker 
2007). 
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5.8.3 Screening of cosurfactants 
As shown in figure 5.3 all the cosurfactants viz., TP, PEG 400, PPG improved the 
emulsification ability of AK 140 and Tween 80 increasing the spontaneity of the 
nanoemulsion formation in varying proportion. Amongst the various cosurfactant 
assorted TP showed most promising results, and was able to reduce the liquid crystal 
structures generally observed with AK140 which could be due to the high solving 
power of TP (Brusewitz, Schendler et al. 2007) . 
 
Figure 5. 3 % transmittance value of various surfactants and cosurfactants 
5.8.4 Construction of ternary phase diagrams 
Ternary phase diagrams were constructed to identify the self- nanoemulsifying region 
and to select a suitable concentration of oil, surfactant and cosurfactant for the 
development of SNEDDS. On the basis of preliminary studies CMCM was selected as 
the oily phase, Tween 80, Labrasol, AK 140 were selected as surfactants, while TP 
was selected as cosurfactant. The phase diagrams of CMCM -Tween 80-TP; CMCM - 
Labrasol -TP; CMCM - AK 140 -TP are shown in figures 5.4. 5.5, 5.6  respectively. 
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The outer parallelogram indicates the area, which was explored for locating 
nanoemulsification region. The filled circles with green border indicate the 
formulation in which nanoemulsions with desired attributes were obtained. From the 
figure it is clear that CMCM - AK 140 -TP showed maximum NE region compared to 
the other systems evaluated which could be due to the reason that as seen from the 
preliminary studies AK 140 showed maximum emulsification efficiency and was able 
to emulsify the oil efficiently which could be attributed to the 18-carbon fatty acid of 
AK 140, which could help AK 140 molecules insert into the CMCM drop surface 
uniformly. In addition, the polyethylene glycol structure in both of them could bind 
together through noncovalent interactions such as hydrogen bonding, which made the 
combination of oil and surfactant much tighter (Li, Shaoling Yi et al. 2011). TP has 
similar diethylene glycol structure, which could bind with their polyethylene glycol 
structures to stabilize the NE further. Furthermore, co-surfactant increases interfacial 
fluidity by penetrating into the surfactant film creating void space among surfactant 
molecules. As Labrasol was an 8–10 carbon fatty acid, and Tween 80 had no 
polyethylene glycol structure, they could not emulsify with CMCM and TP as 
effectively as AK 140.  Hence it was decided to load the CMCM  - AK 140 - TP 
ternary system with GMP. 
 
Figure 5. 4 The ternary phase diagrams of  CMCM -Tween 80-TP 
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Figure 5. 5 The The ternary phase diagrams of CMCM - Labrasol -TP; 
 
Figure 5. 6 The ternary phase diagrams of  CMCM - AK 140 -TP 
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5.8.5 Box Behnken Experimental Design 
BBD was used to optimize and evaluate the main effects, interaction effects and 
quadratic effects of the formulation ingredients of GMP loaded SNEDDS. The drug 
content was kept constant equivalent to 10 mg/gm of the prepared SNEDDS. Based 
on the previous results obtained from ternary phase diagram, the range of each 
component was selected as follows: X1 (200 mg - 400 mg of CMCM), X2 (200 mg - 
300 mg of AK 140) and X3 (75 mg - 125 mg of TP). The % transmittance of diluted 
SNEDDS (Y1), mean droplet size (Y2) and cumulative amount of drug released after 
5 minutes (Y3) were selected as the responses and shown in table 5.1. The observed 
responses showed a large variation, suggesting that the independent variables had a 
significant effect (p<0.05) on the selected dependent variables. 
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Table 5. 1 Layout and observed responses of Box Behnken Experimental Design Batches (average ± standard deviation, n=6.) 
Formulation 
Code 
Level of 
CMCM 
(X1) 
Level of 
AK 140 
(X2) 
Level of 
TP 
(X3) 
% Transmittance 
Value 
(Y1) 
Droplet Diameter 
(nm) 
(Y2) 
% Drug release after 5 min. 
(Y3) 
F1 1 1 0 74.96 ± 3.12 92 ± 2.6 59.24 ± 5.45 
F2 0 0 0 92.09 ± 1.18 52 ± 3.8 75.63 ± 2.63 
F3 0 1 -1 76.23 ± 4.21 80 ± 0.8 66.48 ± 3.56 
F4 -1 0 1 98.91 ± 0.56 34 ± 0.26 79.26 ± 2.48 
F5 -1 0 -1 84.23 ± 1.48 62 ± 1.28 72.25 ± 1.58 
F6 -1 1 0 81.54 ± 0.26 78 ± 1.85 65.66 ± 1.26 
F7 0 0 0 99.41 ± 0.23 38 ± 2.05 78.05 ± 2.68 
F8 1 0 1 86.44 ± 2.58 58 ± 2.09 72.58 ± 4.21 
F9 1 -1 0 89.76 ± 2.06 49 ± 1.58 75.26 ± 3.14 
F10 0 1 1 92.09 ± 3.14 65 ±  2.69 71.24 ± 3.56 
F11 1 0 -1 79.46 ± 3.14 86 ± 3.54 67.58 ± 3.79 
F12 0 -1 -1 96.23 ± 0.24 34 ± 0.02 79.96 ± 1.54 
F13 0 0 0 96.21 ± 0.68 45 ± 1.26 77.05 ± 2.87 
F14 0 -1 1 99.4 ± 0.05 25 ± 0.92 84.54 ± 1.02 
F15 -1 -1 0 99.5 ± 0.12 28 ± 0.87 81.24 ± 1.82 
Translation of Coded Levels in Actual Units 
Variables Level Low (-1) Medium (0) High (1) 
X1 200 mg 300 mg 400 mg 
X2 200 mg 250 mg 300 mg 
X3 75 mg 100 mg 125 mg 
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The coefficients in table 5.2 represents the respective quantitative effect of 
independent variables (X1, X2, and X3) and their interactions on the response (Y3). It 
was seen that all the independent variables had a significant effect on the response 
(p<0.05). The negative sign of the coefficient indicated that increase in the value of 
independent variable decreases the value of response and vice versa. The absolute 
value of the coefficient indicates the magnitude of effect of the independent variable 
on the response; higher the value higher the magnitude. The relationship between the 
dependent and independent variables was further elucidated using response surface 
plots. All the determination coefficients R
2
 are larger than 0.9, indicating that over 
90% of the variation in the response could be explained by the model and the 
goodness of fit of the model was confirmed. The F-ratio was found to be far greater 
than the theoretical value with very low probability of less than 0.0001 for each 
regression model, indicating that the regression model is significant with a confidence 
level of 95%. 
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Table 5. 2 Statistical analysis of BBD Box Behnken Experimental Design Batches 
Observed 
Responses  
b0 X1 X2 X3 X11 X22 X33 X1X2 X1X3 X2X3 Fratio R
2
 
            
  
% 
Transmittance 
Value 
(Y1) 
p value <0.0001 0.005 <0.0001 0.002 0.004 0.08 0.178 0.557 0.186 0.053 
18.357 
97.06 
% 
coefficient 95.9033 -4.195 -7.5088 5.0862 -6.5954 -2.8679 -2.0479 0.09 -1.925 3.1725 
            
Droplet 
diameter 
(Y2) 
p value <0.0001 0.009 <0.0001 0.011 0.018 0.343 0.591 0.644 1 0.691 
13.894 
96.15 
% 
coefficient 45 10.375 22.375 -10 12.875 3.875 3.704 -1.75 0 -1.5 
            
% drug 
release at 5 
min 
(Y3) 
p value <0.0001 0.002 <0.0001 0.003 0.001 0.035 0.59 1 0.504 1 
52.130 
98.94 
% coefficient 76.6667 -3 -7.25 2.75 -4.5833 -2.0833 0.4167 0 -0.5 0 
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The effect of X1(CMCM) and X2 (AK 140) at middle level of X3 (TP) is shown in 
figure 5.7. It is evident from the figure that at lower level (-1) of CMCM , with 
increase in AK140 from lower level (-1) to higher level (+1), a decrease in the drug 
release was seen from 81% to 65%. AK 140 at the lowest level was able to emulsify 
the oil efficiently and further increase in the concentration of AK 140 lead to decrease 
in the drug release which could be attributed to the formation of liquid crystal. 
Visually also it was seen that at higher levels of AK 140, the SNEDDS preconcentrate 
did not dispersed rapidly in the dissolution medium, moreover liquid crystals formed 
might be responsible in decrement in the drug dissolution by increasing the viscosity 
of the system, prolonging the time required for phase transition and finally decreasing 
drug dissolution. While as CMCM was increased from lower level (-1) to higher level 
(+1), a moderate decrease in the drug release was seen from 79.26 % to 72.58 %which 
could be attributed to the fact that as shown in table 5.3 the solubility of GMP was 
followed  AK 140 > TP > CMCM, so when the concentration of CMCM was 
increased the total amount of AK 140 decreased, which resulted in increased droplet 
diameter, in turn decrease in total surface area of the emulsifying membrane layer, 
which might defer drug dissolution.(Li, Shaoling Yi et al. 2011) 
The effect of X2 (AK 140) and X3 (TP) at middle level of X1 (CMCM) is shown in 
the figure 5.8. It was seen that at all levels of TP, there was a decrease in the 
dissolution of GMP with increase in AK140 from lower level (-1) to higher level (+1), 
which could be due to the formation of liquid crystals at higher concentration of 
surfactant.(Zhu, Hong et al. 2009) It was also seen that, when TP was increased from 
lower level (-1) to higher level (+1), at all level of AK 140, the increase in drug 
dissolution was seen which could be ascribed to the fact that higher level of TP would 
reduce the formation of crystal structure which would facilitate the dissolution of 
GMP. Alcohols, when used as cosurfactant, had been found to destroy liquid crystal 
phases(Ivanova, Lindman et al. 2000) and traditionally, Transcutol P had been shown 
to increase surfactant chain disorder, loose the packed structure of interface, and 
increase the mobility of both water and surfactant chains which resulted in the 
reduced viscosity of the liquid crystal.(Taha, Al-Saidan et al. 2004) 
The effect of X1 (CMCM)  and X3 (TP) at middle level of X2 (AK 140) is shown in 
the figure 5.9. It was seen that at lower level (-1) of CMCM, increase in TP from 
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lower level (-1) to higher level (+1), an increase in the dissolution from 72.25 % to 
79.26 % was seen. It is apparent that only that part of GMP which has been 
nanoemulsified, is detected; moreover as seen from the preliminary studies the 
solubility of GMP was more in the TP as compared to CMCM and the GMP 
solubilized in the cosurfactant may dissolve into the medium rapidly even without the 
help of formation of SNEDDS. 
Table 5. 3 Solubility of GMP in various surfactants. (average ± standard 
deviation, n=6). 
Surfactants 
Solubility 
(mg/gm) 
Tween 80 8.257 ±0.291 
Polypropylene 
Glycol 
4.677 ± 0.265 
PEG 400 
15.087 
±0.371 
AK140 
20.813 
±0.272 
Labrasol 9.003 ± 0.197 
Transcutol P 
13.913 ± 
0.208 
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Figure 5. 7 Response surface plot of  AK140 and CMCM vs. % drug released at 5 minutes 
 
Figure 5. 8 surface plot of AK 140 and TP vs. % drug released at 5 minutes 
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Figure 5. 9 Response surface plot of TP and CMCM vs. % drug released at 5 minutes 
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As shown in figure 5.10 a high correlation ( R
2
 = 0.9587) was obtained between 
droplet diameter and % drug released. As shown in batch F1 with droplet diameter 92 
nm showed lowest drug release at 5 minutes i.e. 59.24 %, while the formulation F 14 
having droplet diameter 25 nm showed almost 100 % drug release within 5 minutes. 
Droplet size, which generally depends upon the formulation excipient, is a significant 
part for characterizing SNEDDS. The increased drug released with smaller droplets 
could be attributed to the reason that a larger interfacial area is available with 
decreased droplet diameter. 
 
Figure 5. 10 In vitro dissolution profiles of BBD batches 
 
Figure 5. 11 Optimization plot of GMP loaded SNEDDS 
 
5.8.6 Optimization of formulation components 
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Based on the equation obtained from BBD, optimization of formulation components 
was carried out to prepare a SNEDDS which had 25 nm < Y2 <40nm  and 60% < Y3 
< 85%. The desirability function was applied using response optimizer and an optimal 
D of 0.9943 was obtained at respective levels of X1 (365 mg), X2 (200 mg) and X3 
(118 mg) shown in figure 5.11. A final formulation was prepared as per levels 
obtained in optimization and as shown in table 5.4, and as shown in figure 5.12 the 
droplet diameter of the optimized formulation was found out to be 34.10 nm, which 
was in close agreement with expected value, while as shown in figure 5.13 the 
optimized batch showed significantly (p<0.001) higher drug release as compared to 
pure GMP. Moreover, comparing the dissolution profile of pure drug and optimized 
formulation in pH 7.8 phosphate buffer and pH 1.2 0.1 N HCl it was seen that there 
was no significant difference between the dissolution profile of optimized formulation 
while the dissolution profile for pure drug was significantly different (p < 0.05) in pH 
7.8 phosphate buffer and 0.1 N HCl pH 1.2. Seedher and Kanojia concluded that 
GMP shows pH dependent solubility (Seedher and Kanojia 2008; Seedher and 
Kanojia 2009) and hence there was significant difference between the dissolution of 
pure drug in two different buffers, while the optimized formulation was able to release 
the drug independent of the pH of the dissolution medium. The zeta potential of the 
optimized formulation was found to be -42.17 mV, which suggests that no 
aggregation of droplets took place. The final formulation was stored for six months at 
room temperature and characterized for its stability and results confirmed that the 
formulation did not showed any changes during storage. 
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Table 5. 4 Predicted and observed response for optimized GMP loaded SNEDDS 
Response D value Predicted Observed % Biased 
Droplet diameter 
25 nm < Y2 
<40nm 
0.99899 34.98 34.10 2.51 
% Drug released 
at 5 minutes. 
60% < Y3 < 85% 
0.98976 79.84 78.23 2.01 
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Figure 5. 12 Comparison of in vitro dissolution profile of pure GMP and optimized GMP 
loaded SNEDDS.
 
Figure 5. 13 Droplet diameter distribution of optimized GMP loaded SNEDDS 
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5.8.7 In vivo studies of GMP loaded SNEDDS 
Figure 5.14 shows the mean percentage decrease in blood glucose level (BGL) in 
diabetic rats after administration of optimized SNEDDS formulation of glimepiride 
and pure glimepiride. It is evident that the area under effect curve (AUEC) -values for 
optimized formulation containing glimepiride were higher than the corresponding 
values of pure glimepiride (table 5.5). These differences were found to be significant 
(P < 0.05). The increase AUC values could be attributed to the improved dissolution 
of GMP from optimized SNEDDS formulation as compared to pure GMP. 
 
Figure 5. 14 % Decrease in BGL (Mean ± S.E.) 
 
Table 5.5 Area under effect curve value for different groups 
Group of Animal AUEC (0-8h) 
Control 37.4 
GMP loaded SNEDDS 168.0633 
Pure GMP 94.58167 
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5.9. Conclusion 
BBD was effectively employed to optimize the dissolution of GMP, from SNEDDS 
containing CMCM 8 - AK 140 - TP. All the predetermined independent variables 
were found to affect the dependent variables from the resultant nanoemulsion. The 
optimum formulation prepared by response optimizer through desirability function 
provided a final formulation with D 0.9943 which released 79.85% of GMP within 5. 
The in vivo studies confirmed that SNEDDS loaded GMP showed a significantly 
better AUEC as compared to pure GMP. The improved formulation could offer 
improved drug delivery strategy which might allow concomitant use of GMP with 
food.  
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Abstract 
This study is to improve the dissolution characteristics of a poorly water-soluble drug 
glibenclamide (GLB), by engineering nanocrystals using wet milling by zirconia 
beads. Various formulation and process variables were identified and optimized by 
employing a 3
2
 factorial design at two stages. Based on preliminary studies the 
formulation variables selected were polymer to drug ratio and surfactant to drug ratio. 
The process variables selected were milling speed and milling time. The particle size, 
zeta potential, saturation solubility and % drug released at 10 minutes were selected as 
dependent variables at both stages. Fratio suggested that the predetermined response 
parameters were significantly dependent on the independent variables. An optimum 
desirability of 0.9925 was achieved using response profiler by Statistica
® 
8.0. The 
optimized formulation prepared as per levels obtained through desirability showed a 
close agreement between the predicted and expected values. X ray diffraction studies 
concluded that the crystallinity of prepared nanocrystals was intact and the increased 
dissolution could be ascribed to conversion of un milled drug to nanocrystals. 
Prepared GLB nanocrystals showed a significant improvement in the release as 
compared to pure GLB. 
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6.1 Introduction 
According to the food and drug administration nanoparticulate drug is not a generic 
drug rather is considered as “newdrug”. It is not bioequivalent to its  microcrystalline 
or solubilized form, administered at the same dosage and therefore a nanoparticulate 
drug can be patented.(Singare, Marella et al. 2010) It also offers fewer side effects, 
lower doses and faster onset of action. Nanosuspensions are liquid dispersion 
consisting of solid drug nanoparticles which are stabilized by polymer and or 
surfactant (Liversidge and Liversidge 2011). Nanosizing has been proven to be an 
effective tool for an active moiety considered as “brick dust candidate”. Extensive 
review has been done on the various approaches for development and characterization 
of nanosuspensions (Keck and Müller 2006; Gao, Zhang et al. 2008; Chan and Kwok 
2011; D'Addio and Prud'homme 2011), nevertheless briefly it has been classified in to 
two basic approaches i.e. bottom up technology and top down technology. The bottom 
up technology involves dissolving drug in a solvent which is then added to non-
solvent to precipitate and control the growth of crystals. The top down approach relies 
on mechanical attrition to render large crystalline particles into nanocrystals and their 
small size and increased surface area leads to an increased dissolution rate and 
increased bioavailability. 
Glibenclamide figure 6.1, is a potent sulfonylurea and has established potential 
benefits such as lower dose, rapid onset, lower insulin levels and less-pronounced 
glucagonotropic effects, insulin-sensitizing and insulin-mimetic affects. GLB lowers 
blood glucose level in patients with Type 2 diabetes by directly stimulating the acute 
release of insulin from functioning beta cells of pancreatic islet tissue by binding to 
the SUR1 subunits and block the ATP-sensitive K+ channel, however GLB is a  
poorly soluble drug (< 8ug/ml in pH 7.4 phosphate buffer) (Seedher and Kanojia 
2009) with relatively high permeability through CaCo-2 cell monolayer's which 
warrants it to be classified under  BCS Class II classification (Lindenberg, Kopp et al. 
2004), Otoom et. al. concluded that glyburide administration under fasting condition 
significantly increases area under curve for 24 hours and increases maximum 
concentration of GLB in blood compared to its administration under feeding condition 
and the lag time was significantly reduced in fasting condition compared with feeding 
situation suggesting that it is effectively absorbed from the gastrointestinal tract, 
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however, presence of food, certain dietary supplements interfere with its dissolution 
and in turn its absorption(Otoom, Hasan et al. 2001). In view of the time required to 
reach an optimal concentration in plasma, GLB may be more effective if given 30 
minutes before meal (Hardman and Limbird 2001). Conversely, this might reduce 
patient compliance since if after taking the drug the patient is not able to have the 
meal it would result in severe hypoglycemia and if taken with meal, food sequentially 
would interfere with its absorption. Hence, improving the dissolution characteristics 
of GLB might allow concomitant dosing of the drug with food. Various researchers 
have tried to improve the dissolution characteristics of GLB, but the application of 
nanotechnology drug delivery for improving the dissolution characteristics of GLB is 
still in the early hours. Recently Patravale and Bachhav prepared self 
microemulsifying drug delivery system (SMEDDS) and improved GLB dissolution 
characteristics but concluded that it gets degraded in the prepared SMEDDS (Bachhav 
and Patravale 2009), more recently Singh and coworkers prepared a self nano 
emulsifying drug delivery system (SNEDDS) of GLB and improved the dissolution 
characteristics of GLB (Singh, Verma et al. 2010). However the excessive use of 
surfactants to dissolve the drug may limit the application of the SNEDDS. The same 
groups of coworker also prepared and optimized a nanosuspension formulation using 
GLB as a model drug (Singh, Srinivasan et al. 2011). However, a detailed 
investigation into the preparation of GLB nanosuspensions was lacking and in view of 
all this the present investigation was carried to develop, characterize and optimize 
nanosuspensions of GLB, to improve its dissolution characteristics. Various factors 
such as stabilizer type, stabilizer to drug ratio, milling time, milling speed were 
optimized by applying factorial design at two stages. 
 
Figure 6. 1 Glibenclamide 
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6.2. Materials and methods 
6.2.1 Materials: 
Glibenclamide (GLB) was obtained as gift sample from Cadila Pharmaceuticals 
Limited (Ahmedabad, India). PVP S 630 D (PD) was obtained as gift sample from 
International Specialty Products, Singapore. Poloxamer 188 (PX) was obtained as gift 
sample from Cadila Pharmaceuticals limited (Ahmedabad, India). Tween 80, 
Hydroxypropylmethylcellulose (HPMC), Hydroxypropylcellulose (HPC), 
Hydroxyethylcellulose (HEC) were purchased from S.D.Fine chemicals limited 
(Mumbai, India). Zirconia beads (1.0 mm, 0.1 mm) were purchased from Biospecs 
Limited (New Delhi, India.) 
6.2.2 Methods: 
6.2.2.1 Prepration of GLB nanocrystals: 
GLB nanocrystals were prepared using a wet-milling method. First, the un-milled 
compound and formulation vehicle were mixed in a vial. The beads were then added 
to the vial to achieve a predetermined bead to suspension ratio. A magnetic stir bar 
was added and the vial which was placed on a magnetic stirrer (Remi Instruments Pvt. 
Ltd.) with a digital speed control. The milled suspensions were then collected using 
transfer pipettes and beads were rinsed with formulation vehicle, each time the final 
concentration of suspension was kept at 5mg/ml. The freshly formed suspension was 
centrifuged at 5000 rpm (Remi Centrifuge, Remi Instruments Pvt. Ltd) for 10 minutes 
and washed twice with 5 ml of deionized water. The obtained nanocrystals were oven-
dried at 50 °C overnight and stored in desiccators till further use. 
6.2.2.2 Experimental design 
A randomized 3
2
 full factorial design with two factors at three levels was adopted to 
systematically study the formulation and preparation parameters of GLB nanocrystals. 
The study was divided into two parts; in the first part stabilizer to drug ratio was 
optimized and in the second part milling time and milling speed were optimized. A 
total of nine experimental trials were generated at each stage by Statistica 8.0 
(StatSoft Inc, USA) performed at all possible combinations. The dependent variables, 
particle size (Y1), zeta potential (Y2), saturation solubility (Y3) and % drug dissolved 
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at 10 minutes (Y4) were selected on the basis of trials taken during preliminary 
batches. 
6.3. Characterization of GLB nanocrystals 
6.3.1 Particle Size and Zeta Potential analysis. 
Particle size, size distribution and zeta potential of GLB nanocrystals were determined 
using Zetatrac (Microtrac Inc., USA). Zetatrac utilizes a high frequency AC electric 
field to oscillate the charged particles. The Brownian motion power spectrum is 
analyzed with modulated power spectrum (MPS) technique, a component of power 
spectrum resulting from oscillating particles. 100 mg of sample was suspended with 
sufficient water and suspension samples were directly placed into cuvette and 
measure particle size and zeta potential (Dabhi, Limbani et al. 2011) 
6.3.2 Percentage yield and drug content 
GLB  content was determined by dissolving accurately weighed quantity of GLB 
nanocrystals in methanol. The solutions were filtered, diluted appropriately and 
samples were measured spectrophotometrically at 229.8 nm for the drug content. 
6.3.3 Determination of saturation solubility 
Saturation solubility measurements of GLB nanocrystals were carried out as follows: 
known excess amount of different formulations of GLB was added to 10 ml of 0.05 M 
phosphate buffer (pH 7.5). Samples were sonicated briefly (bath sonicator, Trans o 
Sonic,) for 5 second and stirred in a water bath (37 ± 0.3 °C) for 48 h. Samples were 
then centrifuged, the supernatant was removed, diluted suitably and analyzed 
spectrophotometrically as described earlier. 
6.3.4 In vitro dissolution studies 
Dissolution studies were  carried out in 500 ml 0.05 M pH 7.5 phosphate buffer at 
37°C at 50 rpm (Paddle method, Electrolab Dissolution Tester TDT-06P, USP) 
(USFDA and Guidelines). Ten milligrams of GLB or its equivalent formulations were 
added to dissolution medium and five ml of sample were withdrawn at 10, 20, 30, 45 
and 60 minutes and replaced with fresh media. The solutions were filtered with 
whatman filter paper (0.22 µm) and assayed spectrophotometrically for the dissolved 
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drug at 229.8 nm by the regression equation of standard curve developed in the same 
range in the linearity range of 2-18 µg/ml. 
6.3.5 Powder X-Ray Diffraction Analysis 
Powder X-Ray Diffraction (PXRD) patterns of pure GLB, GLB nanocrystal were 
obtained using Powder X-ray diffractometer (MiniFlex, Rikagu Inc., USA) with a 
copper tube anode over 1–40° 2θ-1 range. The operation data were as follows: 
generator tension (voltage) 45 kV; generator current 40 mA; scan step time 9 s
-1 
and 
scan step size of 0.008° (2θ). 
6.3.6 Statistical evaluation 
The experimental data obtained were validated by ANOVA combined with the F-test. 
The determination coefficient (R
2
, agreement between the experimental results and 
predicted values obtained from the model) and the model F-value (Fisher variation 
ratio, the ratio of mean square for regression to mean square for residual) were 
applied for statistical evaluation. 
6.4 In vivo studies of optimized GLB nanocrystals 
Approval to carry out in vivo study was obtained from Department of Pharmaceutical 
Sciences, Saurashtra University, Institutional Animal Ethics Committee, CPCSEA 
Reg. No. 1155/ac/07/CPCSEA and their guidelines were followed for the studies 
Male wistar rats weighing (~250 gm) were kept on standard diet and fasted over 
night. Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and nicotinamide 
was dissolved in normal physiological saline. Non-insulin-dependent diabetes 
mellitus was induced in overnight fasted rats by a single intraperitoneal injection of 
STZ (45 mg/kg b.w.). 15 min later, the rats were given the intraperitoneal 
administration of nicotinamide (110 mg/kg b.w.). Hyperglycemia was confirmed by 
the elevated glucose levels in plasma, determined at 72 h. The animals with blood 
glucose concentration more than 250 mg/dL were considered to be diabetes and used 
for the experiment (Prabu, Kumarappan et al. 2012). 
The rats were divided into three groups after the induction of STZ-nicotinamide 
diabetes. Animals in the control group received 0.5% carboxy-methyl cellulose 
(CMC) only. The test groups of animals were treated with the test samples suspended 
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in the same vehicle in a parallel group design. Intragastric tubing was used to 
administer a single dose of 600µg/kg of the free drug or the equivalent amount of 
optimized GLB nanocrystals. Blood samples were collected at 1,2,3...8 and 24 h after 
the oral administration of test samples. Blood glucose level (BGL) was measured at 
different time intervals, up to 24 h the hypoglycemic response was evaluated as 
percentage decrease in blood glucose level: 
                 
                   
          
      
The pharmacodynamic parameter of the area under percentage decrease in BGL 
versus time curve (AUC0–8h) was calculated adopting the trapezoidal rule. Statistical 
analysis of the results was performed using one-way analysis of variance (ANOVA). 
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6.5. Results and Discussion 
6.5.1 Preliminary studies 
6.5.1.1 Effect of loading and type of beads. 
The preliminary studies were carried out to evaluate the effect of loading and type of 
zirconia beads. It was seen that loading of zirconia beads had a noteworthy effect on 
the milling power. Various batches prepared by varying the suspension to bead ratio, 
suggested that suspension to bead ratio of 1:1 showed the highest particle size 
reduction and the same was maintained throughout the study. Further to evaluate the 
effect of size of zirconia beads on the milling power, number of batches were 
prepared varying the size and ratio of zirconia beads (1.0 mm and 0.1 mm, in 1:0, 1:2, 
1:1, 2:1, 0:1 ratio) and it was concluded that the batch prepared by milling only with 
0.1 mm of zirconia beads showed better size reduction as compared to other 
combinations which could be attributed to the higher contact surfaces due to 
decreased bead diameter and reducing the dead space due to which more number of 
particles are size reduced. In view of this, 0.1 mm of zirconia beads were employed 
for further studies. 
6.5.1.2. Effect of stabilizer and concentration of stabilizer. 
A suitable stabilizer has to be added to stabilize the nanosuspension system and 
prevent aggregation and Ostwald ripening (Verma, Kumara et al. 2010). Screening for 
an optimal surfactant(s) and its amount is very important for the product quality. In 
view of this a series of stabilizers were assorted for preparing nanosuspension. 
Different formulations were prepared varying the type of stabilizer at a constant ratio 
of 0.5:1 of stabilizer to GLB. The prepared nanosuspensions were evaluated for 
particle size and zeta potential. As shown in figure 6.2, efficient particle size 
reduction was seen with all the stabilizers with no specific pattern been observed. 
Amongst the polymeric group PD showed highest particle size reduction while in the 
surfactant group PX showed highest size reduction. PD chemically is vinyl 
pyrrolidone/vinyl acetate copolymer, and is acknowledged to get adsorb on the 
surface of the drug particle and resist crystal growth, since when two particles 
surrounded by an adsorbed polymer layer approach each other, there will be a local 
increase in polymer concentration in that region which results in an increase in 
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osmotic pressure locally and leads to an increase in total potential energy which might 
be responsible for  preventing of  agglomeration of the particles formed (Verma, Huey 
et al. 2009). While PX is responsible for the hydrophobic interaction with the drug 
molecule and the hydrophobic polypropylene oxide group (PPO) in the polymer 
serves to anchor the copolymer to the particle surface while the polyethylene oxide 
group has little affinity for the surface and is extended into the dispersion medium and 
thus improves the wettability of drug powder in the dispersion medium (Kumar, Rao 
et al. 2008). Visually also it was seen that when only PD was employed the GLB 
particles did not wetted adequately and particles floated on the aqueous vehicle while 
when PX was employed it increased the wettability of GLB particle and coated the 
newly formed surfaces more effectively and hence showed highest particle size 
reduction. However as shown in figure 6.3 the analysis of zeta potential suggested 
that all the batches showed zeta potential less than -20 mV, which suggests that there 
is a probability of agglomerate formation, and in view of this it was decided to 
employ polymer PD and non ionic surfactant PX collectively. 
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Figure 6. 2 Effect of stabilizer on particle size reduction of GLB (average ± standard deviation, n =6)
 
Figure 6. 3 Effect of stabilizer on zeta potential (average ± standard deviation, n =6) 
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6.5.2 Experimental Design 
6.5.2.1 Effect of formulation variables 
Various formulations were prepared varying the ratio of PX and PD with GLB. As 
shown in table 6.1 a 3
2
 full factorial design was used to evaluate the effect of both the 
stabilizers on the predetermined dependent variables viz., particle size, zeta potential, 
saturation solubility and % drug released at 10 minutes. The coefficients in table 6.2 
represents the respective quantitative effect of independent variables (X1' and X2') 
and their interactions on the various responses. It was seen that all the independent 
variables had a significant effect on the response (p<0.05). The negative sign of the 
coefficient indicated that increase in the value of independent variable decreases the 
value of response and vice versa. The absolute value of the coefficient indicates the 
magnitude of effect of the independent variable on the response; higher the value 
higher the magnitude. The relationship between the dependent and independent 
variables was further elucidated using response surface plots. All the determination 
coefficients R
2
 are larger than 0.9, indicating that over 90% of the variation in the 
response could be explained by the model and the goodness of fit of the model was 
confirmed. The F-ratio was found to be far greater than the theoretical value with very 
low probability of less than 0.0001 for each regression model, indicating that the 
regression model is significant with a confidence level of 95%. The observed 
responses showed a wide variation suggesting that the concentration of both the 
stabilizers had a significant effect on resultant particle size, saturation solubility and 
zeta potential. The effect of formulation variables was further elucidated by contour 
plot. In general, as shown in figure 6.4, 5.5 and 5.6, it was seen that at lower level of 
PD to GLB (0.3:1.0) increasing the ratio of PX to GLB from lower level (0.2:1) to 
higher level (0.8:1), decrease in the particle size was seen from 983 nm to 498 nm, 
which could be attributed to the increased wetting of the GLB particles as discussed 
earlier, which in turn improves size reduction efficiency by media milling as well as 
formation of a adsorbed sterically stabilising layer of PX molecules on GLB surface. 
At the same levels the zeta potential also decreased from -18 to -42 mV, since zeta 
potential is the total potential at the hydrodynamic shear plane and can be determined 
from particle mobility under an electric field a decrease in zeta potential primarily 
suggest formation of a sterically stabilising adsorbed polymer layer (Verma, Huey et 
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al. 2009). While it was seen that at middle level of PX to GLB (0.5:1), an increase in 
the ratio of PD to GLB from lower level (0.3:1.0) to higher level (0.9:1.0), a increase 
in particle size from 730 nm to 1256 nm was seen, which appeared  unexpected, since 
PD has been shown to stabilize the milled particles (Itoh, Pongpeerapat et al. 2003). 
However, the increase in particle size could be attributed to the increase in the 
viscosity of the final suspension due to increase in PD, which reduces the milling 
efficiency of zirconia beads and thence a increase in particle size was seen. At the 
same levels an increase in zeta potential was seen from -34mV to -18mV, which 
could be endorsed to the fact that with increase in the PD concentration, PD 
molecules might compete with PX molecules and might hinder the adsorption of PX 
molecules on the surface of the GLB particle, which sequentially reduces the 
formation of a strong stabilizing layer and hence an increase in zeta potential value 
was seen. Check point batches were prepared to validate the mathematical model and 
based on the results obtained it was seen that both the stabilizer were required for 
preparing a stable nanosuspension and the optimum concentration of  each of them 
was 0.3:1 and 0.8:1 of PD : GLB and PX : GLB respectively. 
  
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 104
GLB Nanocrystals 6 
 
Table 6. 1 Layout and observed responses of 3
2
 factorial design for formulation variables (polymer to drug ratio and surfactant to drug ratio) (average ± standard deviation, 
n=6.) 
Batch Code 
Ratio of 
PD:GLB 
(X1') 
Ratio of 
PX:GLB 
(X2') 
d (90) 
(nm) 
(Y1) 
Zeta potential 
(mV) 
(Y2) 
Saturation solubility 
(ug/ml) 
(Y3) 
% drug released 
at 10 minutes. 
 
 X1  X2  Y1 Y2 Y3 Y4 
DP1 -1 -1 983.2 ± 7.3 -18.10 ± 2.3 9.34 ± 1.6 62.45 ± 1.53 
DP2 0 0 547.6 ± 12.6 -25.62 ± 5.2 15.66 ± 0.3 85.24 ± 0.49 
DP3 -1 1 498.5 ± 9.2 -42.11 ± 1.2 17.24 ± 1.9 92.54 ± 0.61 
DP4 0 1 342.3 ± 5.6 -36.63 ± 0.9 19.25 ± 0.5 97.26 ± 0.64 
DP5 1 -1 1752.6 ±  7.8 -12.72 ± 2.2 5.26 ± 2.6 52.26 ± 1.53 
DP6 0 -1 928.6 ± 6.3 -27.21 ± 1.6 10.15 ± 1.2 69.58 ± 1.25 
DP7 1 0 1256.5 ± 10.2 -18.34 ± 0.8 8.24 ± 0.6 61.25 ± 1.01 
DP8 -1 0 730.2 ± 5.9 -34.92 ± 2.1 12.86 ± 1.9 75.21 ± 1.39 
DP9 1 1 982.9 ± 6.2 -26.12 ± 3.2 9.45 ± 0.3 67.28 ± 0.42 
Translation of Coded Levels in Actual Units  
Variables Level Low (-1) Medium (0) Higher (1)  
X1 0.3:1 0.5:1 0.7:1  
X2 0.2:1 0.5:1 0.8:1  
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Table 6. 2 Statistical analysis of 3
2
 factorial design for formulation variables polymer to drug ratio and surfactant to drug ratio. 
Observed 
Responses  
b0 X1' X2' X12' X11' X22' F ratio R
2
 
        
  
Particle size 
(nm) 
p value 0.0002 0.0003 0.0002 0.0325 0.0005 0.0791 
209.11 99.71 % 
coefficient 559.1111 296.5 -306.833 -71.25 427.833 69.8333 
(Y1) 
Saturation 
solubility 
(µg/ml) 
p value 0.0003 0.0097 0.004796 0.2033 0.0106 0.6007 
25.482 97.70 % coefficient 15.3344 -2.7483 3.5316 -0.9275 -4.6216 -0.4716 
(Y2) 
       
% drug 
release at 10 
min 
(Y3) 
p value 0.0001 0.0030 0.0009 0.0458 0.0023 0.8476 
70.015 99.15 % 
coefficient 84.2522 -8.235 12.1316 -3.7675 -15.5283 -0.3383 
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Figure 6. 4 Contour plot of effect of ratio of stabilizer on particle size distribution of GLB nanocrystals 
 
 
Figure 6. 5Contour plot of effect of ratio of stabilizer on saturation solubility of GLB nanocrystals 
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Figure 6.6 Contour plot of effect of ratio of stabilizer on % drug release at 10 minutes distribution of GLB nanocrystals 
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6.5.2.2 Effect of process variables 
In the second part a 3
2
 full factorial design was used to optimize and evaluate the 
main effects, interaction effects and quadratic effects of milling speed (X1) and 
milling time (X2). particle size distribution (Y1), saturation solubility (Y2) and % 
drug released at 10 minutes (Y3) were selected as the response parameters, as shown 
in table 6.3 the observed responses showed a large variation, suggesting that the 
independent variables had a significant effect (p<0.05) on the selected dependent 
variables. 
The coefficients in table 6.4 represent the respective quantitative effect of independent 
variables (X1 and X2) and their interactions on the various responses. The 
relationship between the selected dependent and independent variables was further 
elucidated using response surface plots. As shown in figure 6.7, 6.8 and 6.9 at middle 
level of milling speed (700 rpm), the increase in milling time from lower level (3 hrs) 
to middle level (7 hrs) resulted in a decrease in, particle size from 946 nm to 372 nm, 
an increase in saturation solubility from 10.83 µg/ml to 18.45 µg/ml and increase in 
percentage drug release from 72.66% to 98.36%. The decrease in particle size could 
be attributed to the breaking of GLB particles. However further increase in the milling 
time to a higher level (11 hrs) resulted in, a moderate increase in particle size to 720 
nm, a decrease in saturation solubility to 13.83 and decrease in % drug released to  
82.33 %. This observation could be ascribed to the fact that particle size growth can 
occur due to various reasons such as shortage of excess stabilizer, agglomeration due 
to increased surface energy and re-crystallization of the dissolved drug, which in turn 
affects the saturation solubility and % drug release (Cerdeira, Mazzotti et al. 2010). At 
middle level of milling time (7 hrs) increasing the milling speed from lower level (400 
rpm) to middle level (700 rpm) decreased the particle size from 752 nm to 372 nm, 
increased the saturation solubility from 13.38 µg/ml  to 18.45 µg/ml, and increased 
percentage drug release from 79.23% to 98.36%. The decrease in particle size could 
be due to the fact that increasing the speed, increases the efficiency of the milling by 
generating high energy and shear forces as a result of the impaction of the zirconia 
beads with the GLB particles which subsequently provides the energy input to break 
the raw GLB particles drug into nanoparticles.. However, further increase in speed to 
a higher level (1100 rpm) a slight decrease in particle size to 412 nm was seen which 
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could be due a decrease in attrition between the GLB particles and zirconia beads 
which due to high speed could have wedged to the periphery of the vial and 
subsequently milling efficiency decreased and a higher particle size was obtained. 
Moreover, milling at lower speed for prolonged time and higher speed for shorter time 
resulted in larger particles, which suggested that both milling time as well as milling 
speed had to be optimized for obtaining a narrow size range of particle. 
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Table 6. 3 Layout and observed responses of 3
2
 factorial design for process variables (milling speed and milling time) (average ± standard deviation, n=6.) 
Batch 
Code 
Milling 
Speed 
(rpm) 
X1 
Milling 
Time 
(hrs) 
X2 
d (90) 
(nm) 
 
Y1 
Saturation 
solubility 
(µg/ml) 
Y2 
% drug released 
at 10 minutes. 
Y3 
ST1 -1 0 754.2 ± 13.2 13.38 ± 0.4 79.23 ± 0.81 
ST2 0 0 372.6 ± 12.6 18.45 ± 1.6 98.36 ± 0.86 
ST3 1 1 548.4 ± 4.2 16.12 ± 0.2 87.24 ± 1.01 
ST4 0 -1 946.2 ± 5.9 10.83 ± 0.3 72.66 ± 1.71 
ST5 1 -1 1025.8 ± 12.6 9.78 ± 0.6 66.23 ± 0.52 
ST6 -1 1 945.1 ± 6.3 10.85 ± 0.9 71.66 ± 0.28 
ST7 1 0 412.9 ± 2.9 17.92  ± 1.2 92.27 ± 0.94 
ST8 0 1 720.2 ± 5.4 13.83 ± 2.1 82.73 ± 0.52 
ST9 -1 -1 1458.9 ± 10.2 6.18 ± 1.6 59.29 ± 0.22 
Translation of Coded Levels in Actual Units  
Variables Level Low (-1) Medium (0) Higher (1)  
X1 400 750 1100  
X2 4 8 12  
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Table 6. 4 Statistical analysis  of 3
2
 factorial design for process variables (milling speed and milling time) 
Observed 
Responses  
b0 X1 X2 X12 X11 X22 F ratio R
2
 
        
  
Particle size 
(nm) 
(Y1) 
p value 0.01139 0.01503 0.0135 0.8616 0.0771 0.0078 
20.097 97.10% 
coefficient 394.2222 -195.333 -202.667 9.000 177.6667 427.6666 
Saturation 
solubility 
(µg/ml) 
(Y2) 
p value 0.0001 0.0104 0.0092 0.4471 0.0590 0.0042 
28.168 97.91% 
coefficient 17.92667 2.236983 2.334383 0.41605 -2.00235 -5.32235 
% drug 
release at 10 
min 
(Y3) 
p value 0.0001 0.0209 0.0121 0.2763 0.0334 0.0054 
23.538 97.51% 
coefficient 95.6844 5.9266 7.2416 2.16 -8.5966 -16.6516 
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Figure 6. 7Response surface plot of effect of milling speed and milling time on 
particle size distribution. 
 
Figure 6. 8Response surface plot of effect of milling speed and milling time on 
saturation solubility. 
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Figure 6. 9 Response surface plot of effect of milling speed and milling time on % drug dissolved at 10 minutes 
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6.5.4. Process optimization 
Based on the equation obtained from factorial design, optimization of process 
parameters was carried to prepare GLB nanocrystal, the response Y1 was minimized, 
while Y2 and Y3 was maximized. The desirability function was applied using 
desirability profiler and an optimum D of 0.9925 was obtained at respective levels of 
X1 (870 rpm) and  X2 (8 hrs) as shown in figure 6.10. A final formulation was 
prepared as per levels obtained in optimization and as shown in table 6.5, and as 
shown in figure 6.11, the optimized formulation had d(90) of 329.04 nm and as shown 
in figure 6.11 released almost 100 % of drug within first 10 minutes. Moreover, 
comparing the dissolution profile of pure drug and optimized formulation in pH 7.5 
phosphate buffer and 0.1 N HCl pH 1.2 it was seen that there was no significant 
difference between the dissolution profile of optimized formulation while the 
dissolution profile for pure drug was significantly different (p < 0.05) in pH 7.5 
phosphate buffer and 0.1 N HCl pH 1.2, Seedher and Kanojia concluded that GLB 
shows pH dependent solubility (Seedher and Kanojia 2008; Seedher and Kanojia 
2009) and hence there was significant difference between the dissolution pattern of 
pure drug in two different buffers, while the optimized formulation was able to release 
the drug independent of the pH of the dissolution medium. Moreover as depicted in 
figure 6.12 the PXRD pattern of pure GLB (top) showed sharp and intense peaks 
indicating 2Ɵ values of 11.68, 18.91, 20.96, 23.03 indicating its crystalline nature. 
While in GLB nanocrystals  (bottom) the peaks are almost similar in intensity and 
position, indicating the crystallinity of the drug is intact and the increased dissolution 
as seen from dissolution studies could be attributed to a decrease in particle size from 
um size of pure drug to nanometer size of nanocrystals, which according to Noyes 
Whitney equation increases the saturation solubility and hence dissolution 
characteristics. The zeta potential of the optimized formulation was found to be -34.26 
mV, which suggests that no aggregation of particles took place.  
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Table 6. 5 Observed and predicted response of the optimized batch. 
Response Predicted Observed % Biased 
Particle size 
(nm) 
(Y1) 
324.17 329.04 -1.48 % 
Saturation solubility 
(µg/ml) 
(Y2) 
18.71 18.52 1.01 % 
% drug release at 10 min 
(Y3) 
97.49 98.26 -0.78 % 
 
 
 
Figure 6. 10 Desirability plot for optimization of process variables milling speed and milling time 
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Figure 6. 11 Particle size and size distribution of optimized batch. 
 
Figure 6. 12 Comparison of dissolution profile of optimized batch and pure drug in pH 7.5 phosphate buffer and 
pH 1.2 HCl 
 
Figure 6. 13 a). PXRD spectra of pure GLB b.) PXRD spectra of GLB nanocrystals. 
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6.5.5 In vivo studies of GLB nanocrystals 
Figure 6.14 shows the mean percentage decrease in blood glucose level (BGL) in 
diabetic rats after administration of optimized GLB nanocrystals and pure GLB. It is 
evident that the area under effect curve (AUEC) -values for optimized formulation 
containing GLB were higher than the corresponding values of pure GLB (table 6.6). 
These differences were found to be significant (P < 0.05). The increase AUEC values 
could be attributed to the improved dissolution of GLB from nanocrystals as 
compared to pure GMP. 
 
Figure 6. 14 % Decrease in BGL (Mean ± S.E.) 
 
Table 6.6 Area under effect curve value for different groups 
Group of Animal AUEC (0-8h) 
Control 37.4 
GLB nanocrystals 165.6442 
Pure GLB 97.83333 
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 118
GLB Nanocrystals 6 
 
6.6. Conclusion 
GLB nanocrystals were prepared and the optimized formulation showed better 
dissolution as compared to pure drug. All the predetermined independent variables 
were found to affect the dependent variables from the resultant nanocrystals. The 
factorial design at two levels employed helped in understanding the process of 
nanocystal formation. The optimized formulation maintained the crystallinity of GLB 
and released almost all the drug within 10 minutes. The in vivo studies confirmed that 
GLB nanocrystals showed a significantly better AUEC as compared to pure GLB. 
The improved formulation could offer improved drug delivery strategy which might 
allow concomitant use of GLB with food.  
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Abstract 
This study is to improve the dissolution characteristics of a poorly water-soluble drug 
glibenclamide (GLB), by preparing nanoparticles through liquid anti solvent 
precipitation. A Placket Burman screening design was employed to screen the 
significant formulation and process variables. Total 12 experiments were generated by 
Minitab 16 for screening 5 independent variables namely amount of poloxamer 188 
(PX) (X1), amount of PVP S 630 D (PD) (X2), solvent to antisolvent volume ratio 
(S/AS) (X3), amount of GLB (X4) and speed of mixing (X5). Particle size (Y1), 
saturation solubility (Y2) and % DE5min (Y3) were selected as response variables. all 
of the regression models yielded a good fit with high determination coefficient and F 
value. The pareto chart depicted that all the independent variables except amount of 
drug had a significant effect on the response variables. The mathematical model for 
particle size generated from the regression analysis was given by  PS = 830 - 8.14 PX 
+ 12.8 PD - 11.1 S/AS + 1.42 Drug Conc. - 0.676 Speed (R
2
=93.5, Fratio = 17.28, 
p<0.001). Prepared GLB nanoparticles showed a significant improvement in the 
release as compared to pure GLB with the optimum formulation releasing almost 80 
% drug within first five minutes. X ray diffraction studies concluded that the 
crystallinity of optimum batch nanoparticles was intact and the increased dissolution 
could be ascribed to conversion of un milled drug to nanosized drug.  
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7.1 Introduction 
According to the food and drug administration nanoparticulate drug is not a generic 
drug rather is considered as “newdrug”. It is not bioequivalent to its  microcrystalline 
or solubilized form, administered at the same dosage and therefore a nanoparticulate 
drug can be patented (Singare et al., 2010). It also offers fewer side effects, lower 
doses and faster onset of action. Nanosuspensions are liquid dispersion consisting of 
solid drug nanoparticles which are stabilized by polymer and or surfactant (Liversidge 
& Liversidge, 2011). Nanosizing has been proven to be an effective tool for an active 
moiety considered as “brick dust candidate”. Extensive review has been done on the 
various approaches for development and characterization of nanosuspensions, 
nevertheless briefly it has been classified in to two basic approaches i.e. top down 
technology and bottom up technology. The top down approach relies on mechanical 
attrition to render large crystalline particles into nanocrystals and their small size and 
increased surface area leads to an increased dissolution rate and increased 
bioavailability (Eerdenbrugh, Van den Mooter, & Augustijns, 2008). However, 
breaking drug particles to nanoparticles with size below 100 nm is extremely difficult 
with these methods since these methods are very time consuming and require 
significant energy, which might generate a large amount of  amorphous particles, and 
contamination from milling media or homogenization chamber (Krause, Kayser, 
Ma¨der, Gust, & Mu¨ ller, 2000). The bottom up technology involving solvent 
antisolvent precipitation involves dissolving drug in a solvent which is then added to 
non-solvent to precipitate and control the growth of crystals which produces fine 
particles by starting at the atomic level (Bilati, Allemann, & Doelker, 2005). These 
methods give better control over particle properties such as, size, morphology and 
crystallinity as compared to top-down methods (Thorat & Dalvi, 2012). Other solvent 
removal methods such as, evaporative precipitation into aqueous solution (EPAS) 
(Kakran et al., 2010) and microemulsions have also been reported, though this are 
one-step processes they have certain but have disadvantages such as, low yield and 
degradation of heat sensitive (Zeng, Li, Zhang, & Dong, 2008). The supercritical fluid 
technology is another extensively researched bottom-up technology for precipitation 
of nanoparticles (Kim et al., 2008), however, these processes have inherent 
disadvantages of using extremely high pressures which require high pressure pumps, 
temperatures, and specially designed fine nozzles. High pressure pumps and specially 
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designed nozzles increase the cost of technology. Moreover, fine nozzles may get 
clogged anytime and pose operational problems. 
 
Figure 7. 1 Glibenclamide ((5-chloro-N-(2-(4-(cyclohexylcarbamoyl)amino)sulfonyl)phenyl)ethyl)-2-
methoxybenzamide) 
Glibenclamide [GLB (5-chloro-N-(2-(4-
(cyclohexylcarbamoyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide]  figure 
7.1, is a potent sulfonylurea and has established potential benefits such as lower dose, 
rapid onset, lower insulin levels and less-pronounced glucagonotropic effects, insulin-
sensitizing and insulin-mimetic affects. GLB lowers blood glucose level in patients 
with Type 2 diabetes by directly stimulating the acute release of insulin from 
functioning beta cells of pancreatic islet tissue by binding to the SUR1 subunits and 
block the ATP-sensitive K+ channel, however GLB is a  poorly soluble drug (< 
8ug/ml in pH 7.4 phosphate buffer) (Seedher & Kanojia, 2009) with relatively high 
permeability through CaCo-2 cell monolayer's which warrants it to be classified under  
BCS Class II classification (Lindenberg, Kopp, & Dressman, 2004), Otoom et. al. 
concluded that glyburide administration under fasting condition significantly 
increases area under curve for 24 hours and increases maximum concentration of 
GLB in blood compared to its administration under feeding condition and the lag time 
was significantly reduced in fasting condition compared with feeding situation 
suggesting that it is effectively absorbed from the gastrointestinal tract, however, 
presence of food, certain dietary supplements interfere with its dissolution and in turn 
its absorption(Otoom, Hasan, & Najib, 2001). In view of the time required to reach an 
optimal concentration in plasma, GLB may be more effective if given 30 minutes 
before meal (Hardman & Limbird, 2001). Conversely, this might reduce patient 
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compliance since if after taking the drug the patient is not able to have the meal it 
would result in severe hypoglycemia and if taken with meal, food sequentially would 
interfere with its absorption. Hence, improving the dissolution characteristics of GLB 
might allow concomitant dosing of the drug with food. Various researchers have tried 
to improve the dissolution characteristics of GLB, but the application of 
nanotechnology drug delivery for improving the dissolution characteristics of GLB is 
still in the early hours. Recently Patravale and Bachhav prepared self 
microemulsifying drug delivery system (SMEDDS) and improved GLB dissolution 
characteristics but concluded that it gets degraded in the prepared SMEDDS (Bachhav 
& Patravale, 2009), more recently Singh and coworkers prepared a self nano 
emulsifying drug delivery system (SNEDDS) of GLB and improved the dissolution 
characteristics of GLB (Singh, Verma, & Razdan, 2010). However the excessive use 
of surfactants to dissolve the drug may limit the application of the SNEDDS. The 
same groups of coworker also prepared and optimized a nanosuspension formulation 
using GLB as a model drug (Singh et al., 2011). However, a detailed investigation 
into the preparation of GLB nanoparticles for dissolution enhancement was lacking 
and in view of all this the present investigation was carried to develop, characterize 
and optimize  GLB nanoparticles, to improve its dissolution characteristics. A Placket 
burman screening design was employed to screen various factors such as stabilizer 
type, stabilizer concnetration, drug concentration, solvent and antisolvent volume 
ratio, milling speed for their effect on particle size, saturation solubility and % drug 
released.. 
7.2 Materials and methods 
7.2.1 Materials 
Glibenclamide (GLB) was obtained as gift sample from Cadila Pharmaceuticals 
Limited (Ahmedabad, India). PVP S 630 D (PD) was obtained as gift sample from 
International Specialty Products, Singapore. Poloxamer 188 (PX) was obtained as gift 
sample from Cadila Pharmaceuticals limited (Ahmedabad, India). Tween 80, 
Hydroxypropylmethylcellulose (HPMC), Hydroxypropylcellulose (HPC), 
Hydroxyethylcellulose (HEC) were purchased from S.D.Fine chemicals limited 
(Mumbai, India). Analytical grades of  acetone, dichloromethane, ethyl acetate, 
isopropyl alcohol were purchased from S. D. Fine chemicals limited (Mumbai, India). 
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7.2.2 Preparation of GLB nanocrystals  
GLB nanocrystals were prepared using an liquid antisolvent precipitation technique. 
GLB was dissolved in a solvent at definite concentration and sonicated for 20 
seconds. The solution was filtrated through 0.22µ whatman filter paper to remove 
possible particulate impurities. The prepared GLB solution was injected by syringe 
onto tip of the antisolvent water containing each specific concentration of polymer 
and/or surfactant with stirring. Precipitation took place immediately upon mixing and 
formed a suspension with bluish appearance. The consequences of the formulation 
and process parameters, such as the types of type of solvent, the solvent / antisolvent 
ratio, the stirring rate, and the concentration of GLB on the properties of the formed 
nanoparticles were investigated. The freshly formed suspension was centrifuged at 
5000 rpm (Remi Centrifuge, Remi Instruments Pvt. Ltd) for 10 minutes and washed 
twice with 5 ml of  deionized water, the obtained nanoparticles were then dried at 
50◦C for 8h and stored in desiccators till further use. 
7.2.3 Experimental design 
A set of experiments with Plackett–Burman (PB) screening design was adopted to 
develop nanoparticles of GLB by nanoprecipitation method. PB designs are screening 
designs that involve a large number of factors and relatively few runs. They are 
resolution 3 designs, so they can estimate only main effects. They are typically used 
to identify a few significant factors out of a large set. A total of 12 experimental trials 
involving 5 independent variables were generated by Minitab 16 (USA). The 
independent variables screened were concentration of PX (X1), concentration of PD 
(X2), solvent to anti solvent volume ratio (S/AS) (X3), concentration of GLB (X4) 
and stirring speed (X5). Mean particle size (Y1), Saturation solubility (Y2) and DP 
5min percentage of drug dissolved after 5 minutes (Y3), were selected as the response 
variables on the basis of trials taken during preliminary batches.  
7.3 Characterization of GLB nanocrystals 
7.3.1 Particle Size and Zeta Potential analysis. 
Particle size, size distribution and zeta potential of GLB nanocrystals were determined 
using Zetatrac (Microtrac Inc., USA). Zetatrac utilizes a high frequency AC electric 
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field to oscillate the charged particles. The Brownian motion power spectrum is 
analyzed with modulated power spectrum (MPS) technique, a component of power 
spectrum resulting from oscillating particles. 100 mg of sample was suspended with 
sufficient water and suspension samples were directly placed into cuvette and 
measure particle size and zeta potential (Dabhi, Limbani, & Sheth, 2011) 
7.3.3.2 Percentage yield and drug content  
GLB  content was determined by dissolving accurately weighed quantity of GLB 
nanocrystals in methanol. The solutions were filtered, diluted appropriately and 
samples were measured spectrophotometrically at 229.8 nm for the drug content. 
7.3.3 Determination of saturation solubility 
Saturation solubility measurements of GLB nanocrystals was carried out as follows: 
known excess amount of different formulations of GLB was added to 10 ml of 0.05 M 
phosphate buffer (pH 7.5). Samples were sonicated briefly (bath sonicator, Trans o 
Sonic,) for 5 second and stirred in a water bath (37 ± 0.3 °C) for 48 h. Samples were 
then centrifuged, filtered, diluted suitably and analyzed spectrophotometrically as 
described earlier. 
7.3.4 In vitro dissolution studies 
Dissolution studies were carried out in 500 ml pH 7.5 phosphate buffer at 37°C at 50 
rpm (Paddle method, Electrolab Dissolution Tester TDT-06P, USP). Ten milligrams 
of GLB or its equivalent formulations were added to dissolution medium and five ml 
of sample were withdrawn at 5, 10, 20, 30, 45 and 60 minutes and replaced with fresh 
media. The solutions were filtered with whatman filter paper (0.22 µm) and assayed 
spectrophotometrically for the dissolved drug at 229.8 nm by the regression equation 
of standard curve developed in the same range in the linearity range of 2-18 µg/ml. 
7.3.5 Powder X-Ray Diffraction Analysis 
Powder X-Ray Diffraction (PXRD) patterns of pure GLB, GLB nanocrystal particles 
were obtained using Powder X-ray diffractometer (MiniFlex, Rikagu Inc., USA) with 
a copper tube anode over 1–40° 2θ-1 range. The operation data were as follows: 
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generator tension (voltage) 45 kV; generator current 40 mA; scan step time 9 s
-1 
and 
scan step size of 0.008° (2θ). 
7.3.6 Statistical evaluation 
Dissolution profiles were compared using % DE5min (Area under the dissolution curve 
within 0 and 5 min time interval) which was computed as follows 
      
    
 
 
      
      
           ... 
... ... ... (1) 
The experimental data obtained were validated by ANOVA combined with the F-test. 
The determination coefficient (R
2
, agreement between the experimental results and 
predicted values obtained from the model) and the model F-value (Fisher variation 
ratio, the ratio of mean square for regression to mean square for residual) were 
applied for statistical evaluation. 
7.4 In vivo studies of optimized GLB nanocrystals 
Approval to carry out in vivo study was obtained from Department of Pharmaceutical 
Sciences, Saurashtra University, Institutional Animal Ethics Committee, CPCSEA 
Reg. No. 1155/ac/07/CPCSEA and their guidelines were followed for the studies 
Male wistar rats weighing (~250 gm) were kept on standard diet and fasted over 
night. Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and nicotinamide 
was dissolved in normal physiological saline. Non-insulin-dependent diabetes 
mellitus was induced in overnight fasted rats by a single intraperitoneal injection of 
STZ (45 mg/kg b.w.). 15 min later, the rats were given the intraperitoneal 
administration of nicotinamide (110 mg/kg b.w.). Hyperglycemia was confirmed by 
the elevated glucose levels in plasma, determined at 72 h. The animals with blood 
glucose concentration more than 250 mg/dL were considered to be diabetes and used 
for the experiment (Prabu, Kumarappan, Christudas, & Kalaichelvan, 2012) 
The rats were divided into three groups after the induction of STZ-nicotinamide 
diabetes. Animals in the control group received 0.5% carboxy-methyl cellulose 
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(CMC) only. The test groups of animals were treated with the test samples suspended 
in the same vehicle in a parallel group design. Intragastric tubing was used to 
administer a single dose of 600µg/kg of the free drug or the equivalent amount of 
optimized GLB nanoparticles. Blood samples were collected at 1,2,3...8 and 24 h after 
the oral administration of test samples. Blood glucose level (BGL) was measured at 
different time intervals, up to 24 h the hypoglycemic response was evaluated as 
percentage decrease in blood glucose level: 
                 
                   
          
      
The pharmacodynamic parameter of the area under percentage decrease in BGL 
versus time curve (AUC0–8h) was calculated adopting the trapezoidal rule. Statistical 
analysis of the results was performed using one-way analysis of variance (ANOVA). 
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7.5 Results and Discussion 
7.5.1. Preliminary studies 
7.5.1.1. Effect of the types of solvent and anti-solvent 
The preliminary study was aimed to screen the optimal solvent and antisolvent system 
that together could aid the formation of nanoparticles. The solubility of drug was 
found out in various organic solvents to find out the most suitable solvent which had 
maximum drug loading and provided high supersaturation resulting in rapid 
nucleation and precipitation. It was seen that amongst the various organic solvent 
assorted, acetone showed highest solubility for GLB (drug loading up to ~ 80 mg/ml) 
and was selected as the solvent phase. Water was then selected as the antisolvent 
phase, since acetone is highly miscible with water to go along with by GLB's poor 
aqueous solubility assisting the precipitation process. 
7.5.1.2. Effect of stabilizer and concentration of stabilizer 
A suitable stabilizer has to be added to stabilize the nanosuspension system and 
prevent aggregation and Ostwald ripening (Sudhir  Verma, Kumara, Gokhale, & 
Burgess, 2010). Screening for an optimal surfactant(s) and its amount is very 
important for the product quality. In view of this a series of stabilizers were assorted 
for preparing nanoparticles. Different formulations were prepared varying the type of 
stabilizer at a constant concentration of stabilizer. The prepared nanosuspensions were 
evaluated for particle size. As shown in figure 7.2, amongst the polymeric group PD 
showed highest particle size reduction while in the surfactant group PX showed 
highest size reduction. However as depicted from figure 7.3 no individual stabilizer 
showed sufficient zeta potential for developing nanoparticles and hence it was 
decided to employ both PD as well as PX to prepared GLB nanoparticles. 
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Figure 7. 2 Effect of stabilizer on particle size reduction
 
Figure 7. 3  Effect of stabilizer on zeta potential  
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Figure 7. 4 Estimate of the effect of various independent variables on particle size 
7.5.2 Experimental Design:   
Plackett Burman (PB) designs are screening designs that involve a large number of 
factors and relatively few runs. They are resolution 3 designs, so they can estimate 
only main effects. They are typically used to identify a few significant factors out of a 
large set. As shown in table 7.1 the selected response parameters showed a wide 
variation suggesting that the independent variables had a significant effect on the 
response parameters chosen. Figure 7.4 reveals speed had maximum standardized 
effect at 95 % confidence interval, while the concentration of drug did not had a 
significant effect on particle size. Equation 2-4 suggests that all of the regression 
models yielded a good fit with high determination coefficient and F value. The 
determination coefficients (R2) are larger than 0.9, indicating that over 90% of the 
variation in the response could be explained by the model and the goodness of fit of 
the model was confirmed. The obtained F value is compared with the theoretical value 
(Fisher test critical value) Fα (p-1,N-p) (α, chosen risk, p the number of terms of the 
model, N the number of the experiments) to test the significance of the regression 
model. The theoretical value F0.05 (5,4) is 6.25. As shown in table 7.2, the F-ratio 
was found to be far greater than the theoretical value with very low probability of less 
than 0.001 for each regression model, indicating that the regression model is 
significant with a confidence level of 95%. The significance F and R
2
 suggested that 
there was a good linearity between the predicted and the observed values. All the 
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independent parameters significantly affected the response parameters except drug 
concentration.  
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Table 7. 1 : Layout and observed responses of Placket Burman design batches (average ± standard deviation, n=6.) 
  
Batch Code 
PX 
(mg) 
(X1) 
PD 
(mg) 
(X2) 
S/AS 
(X3) 
Drug 
(mg) 
(X4) 
Speed 
(rpm) 
(X5) 
Particle Size 
(nm) 
(Y1) 
 
Saturation  
Solubility 
(µg/ml) 
(Y2) 
% DE5min. 
(Y3) 
PB1 30 10 20 40 300 316.2 ± 6.1 18.54 ± 1.2 31.52 ± 0.45 
PB2 30 20 10 80 300 678.6 ± 12.6 13.99 ± 0.6 19.43 ± 0.14 
 
PB3 15 20 20 40 800 208.4 ± 4.6 23.98 ± 2.4 45.32 ± 0.68 
PB4 30 10 20 80 300 345.6 ± 12.1 17.56 ± 1.2 29.02 ± 1.24 
PB5 30 20 10 80 800 286.1 ± 5.3 19.56 ± 0.8 35.17 ± 0.98 
PB6 30 20 20 40 800 214.3 ± 4.5 23.25 ± 0.7 41.26 ± 0.55 
PB7 15 20 20 80 300 692.2 ± 6.6 13.78 ± 2.9 19.18 ± 0.68 
PB8 15 10 20 80 800 205.4 ± 3.1 24.31 ± 1.1 46.20 ± 0.98 
PB9 15 10 10 80 800 279.9 ± 5.9 20.39 ± 1.9 39.45 ± 0.32 
PB10 30 10 10 40 800 109.2 ± 4.3 24.94 ± 0.7 47.74 ± 0.66 
PB11 15 20 10 40 300 621.5 ± 10.2 13.48 ± 2.6 19.39 ± 0.21 
PB12 15 10 10 40 300 676.1 ± 14.5 13.86 ± 0.7 20.53 ± 2.55 
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Mathematical equation generated from the regression analysis 
                                    
 
  
                                         
           ... ... ... ... 
(2) 
                           
 
  
                                     
           ... ... ... ... 
(3) 
                                
 
  
                                        
           ... ... ... ... 
(4) 
 
Table 7. 2 Results of regression analysis 
Response variables 
Regression analysis 
R
2
 Fcalc p value 
PS 93.5 17.28 < 0.001 
SS 96.4 32.00 < 0.0001 
% DE5min 96.6 33.65 < 0.0001 
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7.5.2.1 Effect of PX 
The concentration of PX had a significant effect on the particle size. The negative 
value of  the coefficient in equation 2 suggested that increase in the concentration of 
PX decreased the particle size. PX is responsible for the hydrophobic interaction with 
the drug molecule and the hydrophobic polypropylene oxide group (PPO) in the 
polymer serves to anchor the copolymer to the particle surface while the polyethylene 
oxide group has little affinity for the surface and is extended into the dispersion 
medium and thus improves the wettability of drug powder in the dispersion medium 
(Kumar, Rao, & Apte, 2008) which may contribute to a reduction in mean particle 
size due to the surface active properties of the PX. Visually also it was seen that when 
only PD was employed the GLB particles did not wetted adequately and particles 
floated on the aqueous vehicle while when PX was employed it increased the 
wettability of GLB particle and coated the newly formed surfaces more effectively 
and hence showed better particle size reduction. 
7.5.2.2 Effect of PD 
As shown in equation 2 the concentration of PD had a significant effect on the particle 
size. The positive value of  the coefficient suggested that increase in the concentration 
of PD resulted in increased particle size. PD chemically is vinyl pyrrolidone/vinyl 
acetate copolymer, and is acknowledged to get adsorb on the surface of the drug 
particle and resist crystal growth, as when two particles surrounded by an adsorbed 
polymer layer approach each other, there will be a local increase in polymer 
concentration in that region which result in a increase in osmotic pressure locally and 
leads to an increase in total potential energy which might be responsible for  
preventing of  agglomeration of the particles formed (Sudhir Verma, Huey, & 
Burgess, 2009). However, a further increase in the concentration of PD could result in 
a decrease in an appropriate diffusion of the solvent toward the antisolvent caused by 
the high viscosity of the solution, which in turn increases the particle size. 
7.5.2.3 Effect of solvent to antisolvent volume ratio:  
The effect of the S/AS volume ratio was investigated and from the ANOVA results as 
shown in equation 2 the coefficient for S/AS volume ratio has negative sign indicating 
that as S/AS as volume ratio was increased from 1:10 to 1:20, the decrease in particle 
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size was observed. As soon as the solvent is added to anti solvent nuclei are formed 
and growth of nuclei occurs simultaneously. For the consequent growth a high solvent 
to anti-solvent ratio would increase the diffusion distance for growth species and thus 
diffusion becomes the limiting step for nuclei growth. Hence increasing the S/AS 
volume ratio would decrease the particle size formed. 
7.5.2.4 Effect of drug concentration.  
The drug concentration was varied at two levels viz., 40 mg and 80 mg. As shown in 
figure 7.4 the p value for drug concentration was found to be less than 0.05 indicating 
that drug concentration did not affected the particle size significantly. This could be 
due to the high solubility of GLB in the solvent acetone which subsequently shows 
very less variation in the viscosity of the final drug solution. 
7.5.2.5 Effect of speed 
As shown in equation 2 the p value for speed was found to be > 0.001 which 
suggested that speed of mixing had a highly significant effect on particle size. The 
coefficient for effect of speed was negative indicating that increasing the speed of 
mixing decreased the particle size. The decreasing of the particle size can be 
explained by the intensification of the micromixing (i.e. mixing on the molecular 
level) between the multi-phases with the increasing of stirring speed. High 
micromixing efficiency enhanced the mass transfer and the rate of diffusion between 
the multiphase, which induced high homogenous supersaturation in short time and 
thus rapid nucleation to produce smaller drug particles. 
7.5.3 Effect of independent variables on saturation solubility and DE5min. 
As shown in figure 7.5 and 7.6 a high correlation ( r
2
 = 0.9587) was obtained between 
size of nanoparticles and % drug released, it was seen that batch PB 10 with droplet 
diameter 109 nm released almost all the drug within five minutes with DE5min 47.74,  
while the formulation PB 7 having droplet diameter 692 nm showed 42.68 % drug 
release within 5 minutes, with DE5min 19.18. Nanoparticle size, which generally 
depends upon the formulation and process variables, is a significant part for 
improving drug release and the increased drug released as seen from dissolution 
studies with decreased nanoparticle size could be attributed to the reason that 
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according to Noyes Whitney equation increases the saturation solubility and hence 
improves dissolution characteristics.  
 
Figure 7. 5 In vitro dissolution studies of batches PB1-PB6 
 
Figure 7. 6 In vitro dissolution studies of batches PB7-PB12 
However batch PB 9 could be considered as optimum batch, since it allows higher 
drug concentration at lower excipient level and as shown in figure 7 has particle size 
of 209 nm and as depicted in figure 8 releases almost 80 % drug within first 5 minutes 
which is significantly (p<0.001) higher as compared to pure GLB.  
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Figure 7. 7 Particle size and size distribution of optimum batch PB 9. 
 
Figure 7. 8 Comparison of dissolution profile of optimum batch and pure drug in pH 7.5 phosphate buffer and 
pH 1.2 HCl 
Moreover, comparing the dissolution profile of pure drug and optimized formulation 
in pH 7.5 phosphate buffer and pH 1.2 0.1 N HCl it was seen that there was no 
significant difference between the dissolution profile of optimized formulation while 
the dissolution profile for pure drug was significantly different (p < 0.05) in pH 7.5 
phosphate buffer and 0.1 N HCl pH 1.2. Seedher and Kanojia concluded that GMP 
shows pH dependent solubility (Seedher and Kanojia, 2008; Seedher and Kanojia, 
2009) and hence there was significant difference between the dissolution of pure drug 
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in two different buffers, while the optimized formulation was able to release the drug 
independent of the pH of the dissolution medium. 
As shown in figure 7.9 the PXRD pattern of pure GLB  showed sharp and intense 
peaks at 2Ɵ values of 11.68, 18.91, 20.96, 23.03 indicating its crystalline nature. 
While in GLB nanoprecipitates of batch PB 9 (bottom) the peaks are almost similar in 
intensity and position, indicating the crystallinity of the drug is intact and the 
increased dissolution as seen from dissolution studies could be attributed to a decrease 
in particle size from micrometer size of pure drug to nanometer size of nanoparticles. 
The zeta potential of the optimum batch was found to be -35.09 mV, which suggests 
that no aggregation of nanoparticles took place. 
 
Figure 7. 9 PXRD spectra of pure GLB b.) PXRD spectra of GLB nanocrystals.  
            Department of Pharmacuetical Sciences, Saurashtra University, Rajkot 138
GLB nanoparticles 7 
 
7.5.4 In vivo studies of GLB nanoparticles 
Figure 7.10 shows the mean percentage decrease in blood glucose level (BGL) in 
diabetic rats after administration of optimized GLB nanoparticles and pure GLB. It is 
evident that the area under effect curve (AUEC) -values for optimized formulation 
containing GLB were higher than the corresponding values of pure GLB (table 7.3). 
These differences were found to be significant (P < 0.05). The increase AUEC values 
could be attributed to the improved dissolution of GLB from optimum GLB 
nanoparticles formulation as compared to pure GLB. 
 
Figure 7.10 % Decrease in BGL (Mean ± S.E.) 
 
Table 7.3 Area under effect curve value for different groups 
Group of Animal AUEC (0-8h) 
Control 37.4 
GLB nanoparticles 176.7433 
Pure GLB 97.83333 
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7.6 Conclusion: 
GLB nanoparticles were prepared by nanoprecipitation, Placket Burman screening 
design helped in identifying the significant parameters that affected the response 
variables. All the predetermined independent variables except drug concentration 
were found to affect the dependent variables The optimized formulation maintained 
the crystallinity of GLB and released almost 80 % drug within 5 minutes. The in vivo 
studies confirmed that GLB nanocrystals showed a significantly better AUEC as 
compared to pure GLB. The improved formulation could offer improved drug 
delivery strategy which might allow concomitant use of GLB with food. 
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8. Summary and Conclusions 
Sulfonylurea class of drugs has established potential benefits for treatment of diabetes 
mellitus which is the commonest endocrine disorder. However they are poorly soluble 
drugs with relatively high permeability through CaCo-2 cell monolayer's, which 
warrant it to be classified under BCS Class II classification. Two anti-diabetic drugs 
namely glibenclamide and glimepiride; representative of sulfonylurea class; owing to 
their poor solubility, short biological half life, potent dose were selected for 
incorporation in to either a self nanoemulsifying drug delivery system or preparing 
drug nanocrystals for improving dissolution characteristics. 
A self nanoemulsifying drug delivery system was prepared for improving the 
dissolution characteristics of glimepiride. Capmul MCM C8 was found to be the most 
suitable oily phase based on the solubility of glimepiride; Ackrysol K 140 was then 
screened as the preeminent surfactant from the available surfactants based on its 
emulsification ability, while Transcutol P was found to be suitable cosurfactant to 
emulsify the ternary system. Ternary phase diagrams revealed that highest 
nanoemulsifcation region was observed with Capmul MCM C8, Ackrysol K 140 and 
Transcutol P. Box Behnken Experimental Design (BBD) was used to optimize and 
evaluate the main effects, interaction effects and quadratic effects of the formulation 
ingredients of GMP loaded SNEDDS. All the predetermined independent variables 
were found to affect the dependent variables. The optimum formulation prepared by 
response optimizer through desirability function provided a final formulation with D 
0.9943 which released 79.85% of GMP within 5 minutes. The in vivo studies carried 
out suggested that optimized GMP loaded SNEDDS showed significantly higher Area 
Under Effect Curve (AUEC) as compared to pure GMP, which could be attributed to 
improved dissolution of GMP from SNEDDS. 
The second part of the investigation was to prepare glibenclamide nanocrystals for 
improved dissolution characteristics. Glibenclamide nanocrystals were prepared 
namely by media milling method and by nanoprecipitation method. 
In preparation of glibenclamide nanocrystals by media milling, preliminary studies 
revealed that amongst the various formulation excipient assorted PVP S 630 D and 
Poloxamer 188 were found to efficient polymers for particle size reduction. A 3
2
 full 
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factorial design employed to study combined linear and interaction effect of 
formulation variables namely the above mentioned polymers revealed that both 
poloxamer 188 and PVP S 630 D had a significant effect on the dependent variables. 
A 3
2
 full factorial design was then employed to evaluate linear and interaction effect 
of process variables namely milling speed and milling time, which revealed that both 
the independent variables had a significant effect on the predetermined dependent 
variables. The process optimization was then carried out using Statistica8.0 and the 
nanocrystals of the optimized batch released almost all the drug within first 10 
minutes maintaining the crystallinity as depicted by the powder x ray diffractometry 
studies. The improved dissolution of GLB nanocrystals may be responsible for higher 
AUEC of GLB nanocrystals as compared to pure GLB as seen from in vivo studies 
carried out on male wistar rats. 
In the subsequent part glibenclamide nanoparticles were prepared by liquid anti-
solvent precipitation. A Plackett Burman screening design employed to screen five 
independent variables revealed that all the predetermined independent variables 
except drug concentration were found to affect the dependent variables significantly. 
The optimum formulation maintained the crystallinity of glibenclamide and released 
almost 80 % drug within first 5 minutes. The in vivo studies carried depicted that GLB 
nanoparticles showed higher AUEC as compared to pure GLB which could be 
ascribed to the improved dissolution of GLB nanoparticles as seen from in vitro 
studies. 
From the investigation carried out it could be concluded that self nanoemulsifying 
drug delivery system and nanocrystal technology could be employed for improving 
the dissolution characteristics of sulfonylurea class of drugs which might allow 
concomitant administration of drug with food and offer improved patient compliance. 
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Application of Placket Burman Screening Design for Preparing Glibenclamide Nanoparticles for 
Dissolution Enhancement 
S. Shah 1, J. Chavda 1, R. Parikh 2, N. Sheth 3 
1
 BK Mody Government Pharmacy College, 2 RP College of Pharmacy, 3 Saurashtra University 
Purpose 
This study is to improve the dissolution characteristics of a poorly water-soluble drug glibenclamide (GLB), by preparing 
nanoparticles through liquid anti solvent precipitation. 
Methods 
A Placket Burman screening design was employed to screen the significant formulation and process variables. Total 12 
experiments were generated by Minitab 16 for screening 5 independent variables namely amount of poloxamer 188 (PX) 
(X1), amount of PVP S 630 D (PD) (X2), solvent to antisolvent volume ratio (S/AS) (X3), amount of GLB (X4) and speed of 
mixing (X5).Particle size (Y1), saturation solubility (Y2) and % DE5min (Y3) were selected as response variables. 
Results 
All of the regression models yielded a good fit with high determination coefficient and F value. The pareto chart (Figure 
1)depicted that all the independent variables except amount of drug had a significant effect on the response variables. The 
mathematical model for particle size generated from the regression analysis was given by  PS = 830 - 8.14 PX + 12.8 PD - 
11.1 S/AS + 1.42 Drug Conc. - 0.676 Speed (R2=93.5, Fratio = 17.28, p<0.001). The optimum batch of prepared nanoparticles 
had a particle size of 205 nm (Figure 2)and showed a significant (p < 0.05) improvement in the release as compared to pure 
GLB (Figure 3)releasing almost all drug within first five minutes. X ray diffraction studies concluded that the crystallinity of 
nanoparticles of optimum batch was intact and the increased dissolution could be ascribed to conversion of unmilled drug to 
nanosized drug. 
Conclusion 
GLB nanoparticles were prepared by nanoprecipitation, Placket Burman screening design helped in identifying the 
significant parameters that affected the response variables. The optimized formulation maintained the crystallinity of GLB 
and  showed improved dissolution as compared to pure drug.
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Studies in formulation development and process optimization for preparing glibenclamide nanocrystals 
to improve dissolution characteristics 
S. Shah 1, J. Chavda 1, R. Parikh 2, N. Sheth 3 
1
 B K Mody Government Pharmacy College, 2 RP College of Pharmacy, 3 Department of Pharmaceutical Sciences, 
Saurashtra University 
Purpose 
This study is to improve the dissolution characteristics of a poorly water-soluble drug glibenclamide (GLB), by engineering 
nanocrystals using wet milling by zirconia beads. 
Methods 
Various formulation and process variables were identified and optimized by employing a 32 factorial design at two stages. 
Based on preliminary studies the formulation variables selected were polymer to drug ratio and surfactant to drug ratio. The 
process variables selected were milling speed and milling time. The particle size, zeta potential, saturation solubility and % 
drug released at 10 minutes were selected as dependent variables at both stages 
Results 
Statistical evaluation suggested that the predetermined response parameters were significantly dependent on the independent 
variables. As shown in figure 1 an optimum desirability of 0.9925 was achieved using response profiler by Statistica® 8.0. 
The optimized formulation prepared as per levels obtained through desirability showed a close agreement between the 
predicted and expected values. X ray diffraction studies concluded that the crystallinity of prepared nanocrystals was intact 
and as shown in figure 2 the increased dissolution could be ascribed to conversion of un milled drug to nanocrystals. 
Conclusion 
GLB nanocrystals were prepared and the optimized formulation showed better dissolution as compared to pure drug. All the 
predetermined independent variables were found to affect the dependent variables from the resultant nanocrystals. The 
factorial design at two levels employed helped in understanding the process of nanocrystal formation. The optimized 
formulation maintained the crystallinity of GLB and released almost all the drug within 10 minutes.
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Self nanoemulsifying drug delivery system of glimepiride: Design, development and optimization. 
S. Shah 1, J. Chavda 2, R. Parikh 3, N. Sheth 4 
1
 B K Mody Government Pharmacy College, 2 BK Mody Government Pharmacy College, 3 RP College of Pharmacy, 4 
Department of Pharmaceutical Sciences, Saurashtra University 
Purpose 
The objective of the present investigation was to develop and characterize the self nanoemulsifying drug delivery system 
(SNEDDS) of glimepiride (GMP) a poorly soluble drug, for improving its dissolution characteristics. 
Methods 
Solubility of GMP in various vehicles was determined and ternary phase diagrams were constructed using a suitable oil, 
surfactant and cosurfactant system to find out the efficient self emulsification system. A three factor three level Box Behnken 
statistical design(BBD) was employed to explore the main and interaction effect of independent variables namely X1 
(amount of Capmul MCM), X2 (amount of Acrysol K 140), and X3 (amount of Transcutol P). % Transmittance value (Y1), 
droplet diameter (Y2) and % drug released at 5 minutes (Y3) were the dependent variables. Formulation optimization was 
carried out to optimize the droplet diameter and % drug dissolved at 5 minutes. 
Results 
The results clearly indicated that Acrysol K 140 showed the highest emulsification efficiency; amongst the various 
cosurfactant assorted Transcutol P showed most promising results. Box Behnken statistical design revealed that the observed 
responses showed a large variation, suggesting that the independent variables had a significant effect (p<0.05) on the selected 
dependent variables. A final formulation was prepared as per levels obtained in optimization as shown in figure 1, and as 
shown in figure 2 the droplet diameter of the optimized formulation was found out to be 34.10 nm, which was in close 
agreement with expected value, while as shown in figure 3 the optimized batch showed significantly (p<0.001) higher drug 
release as compared to pure GMP. 
Conclusion 
BBD was effectively employed to optimize the dissolution of GMP, from SNEDDS containing Capmul MCM - Acrysol K 
140 - Transcutol P. The optimum formulation prepared by response optimizer through desirability function provided a final 
formulation with D 0.9943 which released 79.85% of GMP within 5 minutes.
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Plackett–Burman screening designThis study is to improve the dissolution characteristics of a poorly water-soluble drug glibenclamide (GLB),
by preparing nanoparticles through liquid anti solvent precipitation. A Plackett–Burman screening design
was employed to screen the signiﬁcant formulation and process variables. A total of 12 experiments were
generated by Minitab® 16 for screening 5 independent variables namely the amount of poloxamer 188
(PX) (X1), amount of PVP S 630 D (PD) (X2), solvent to antisolvent volume ratio (S/AS) (X3), amount of
GLB (X4) and speed of mixing (X5). Mean particle size (Y1), saturation solubility (Y2) and % dissolution ef-
ﬁciency (%DE5min) (Y3) were selected as response variables. All the regression models yielded a good ﬁt
with high determination coefﬁcient and F value. The Pareto chart depicted that all the independent variables
except the amount of GLB had a signiﬁcant effect (pb0.001) on the response variables. The mathematical
model for mean particle size (PS) generated from the regression analysis was given by PS=830−8.14
PX+12.8 PD−11.1 S/AS+1.42 GLB Conc.−0.676 speed of mixing (R2=93.5, Fratio=17.28, pb0.001). Pre-
pared GLB nanoparticles exempliﬁed a signiﬁcant improvement (pb0.05) in the release as compared to
pure GLB with the optimum formulation releasing almost 80% drug within ﬁrst 5 min. The X-ray diffraction
studies concluded that the crystallinity of nanoparticles from the optimum batch was intact and the in-
creased dissolution could be ascribed to conversion of unmilled GLB to nanoparticles.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
According to the food and drug administration nanoparticulate drug is
not a generic drug rather is considered as “newdrug”molecule and is not
bioequivalent to its microcrystalline or solubilized form administered at
the same dose and therefore it can be patented [1]. Nanosuspensions
are liquid dispersion consisting of solid drug nanoparticles, stabilized by
polymer and/or surfactant offering, fewer side effects, lower doses and
faster onset of action [2]. Extensive review has been done on the various
approaches for the development and characterization of nanoparticles,
nevertheless brieﬂy it has been classiﬁed into two basic approaches i.e.
top down technology and bottomup technology. The top down approach
relies on mechanical attrition to render large crystalline particles into
nanocrystals and their reduced size and increased surface area lead to
an increased dissolution ratewhichmay offer an increased bioavailability
[3]. However, breaking large crystalline drug particles to nanoparticles
with size below 100 nm is extremely difﬁcult with these methods since
these methods are very time consuming and require signiﬁcant energy,
which might generate a large amount of amorphous particles, and
contamination from milling media or homogenization chamber [4]. The+91 281 2384279.
.
rights reserved.
cuetical Sciences, Saurbottom up technology involving solvent antisolvent precipitation tech-
nique requires dissolving the drug in a solvent which is then added to a
non-solvent to precipitate the crystals and the subsequent growth of crys-
tal is controlled by the addition of polymer and/or surfactant to produce
ﬁne particles [5]. These methods give better control over particle proper-
ties such as, size, morphology and crystallinity as compared to top-down
methods [6]. Other solvent removalmethods such as, evaporative precip-
itation into aqueous solution (EPAS) [7] and microemulsions have also
been reported, though these are one-step processes they have certain dis-
advantages such as low yield, degradation of heat sensitive materials, etc.
[8]. The supercritical ﬂuid technology is another extensively researched
bottom-up technology for the preparation of nanoparticles [9], however,
it has inherent disadvantages of using extremely high pressureswhich re-
quire high pressure pumps, temperatures, and specially designed ﬁne
nozzles which may pose operational problems.
Glibenclamide [GLB (5-chloro-N-(2-(4-(cyclohexylcarbamoyl)amino
sulfonyl)phenyl)ethyl)-2-methoxybenzamide] in Fig. 1, is a potent sulfo-
nylurea and has established potential beneﬁts such as lower dose, rapid
onset, lower insulin levels and less-pronounced glucagonotropic effects,
insulin-sensitizing and insulin-mimetic affects. However it is a poorly
soluble drug (b8 μg/ml in pH 7.4 phosphate buffer) [10] with relatively
high permeability through CaCo-2 cell monolayer's which warrants it
to be classiﬁed under BCS Class II classiﬁcation [11]. Otoom et al.ashtra University, Rajkot 163
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